Luna Innovations (LUNA) S-49 Feb 15Registration of securities issued in business combination transactionsFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014
Document And Entity Information [Abstract]
Document Type	S-4
Amendment Flag	FALSE
Document Period End Date	30-Sep-14
Trading Symbol	LUNA
Entity Registrant Name	LUNA INNOVATIONS INC
Entity Central Index Key	1239819
Entity Filer Category	Smaller Reporting Company

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Current assets:
Cash and cash equivalents	$14,430,156	$7,778,541	$6,340,461
Accounts receivable, net	5,267,953	5,408,281	7,059,635
Inventory, net	3,400,132	3,346,177	3,336,916
Prepaid expenses	675,933	708,974	667,773
Other current assets	220,207	70,208	35,629
Total current assets	23,994,381	17,312,181	17,440,414
Property and equipment, net	1,917,164	2,060,709	2,426,638
Intangible assets, net	180,718	288,475	437,839
Other assets	1,995	42,710	152,877
Total assets	26,094,258	19,704,075	20,457,768
Current Liabilities:
Current portion of long term debt obligation	1,000,000	1,500,000	1,500,000
Current portion of capital lease obligation	69,675	66,617	54,091
Accounts payable	1,508,790	1,401,764	1,797,571
Accrued liabilities	3,458,456	3,546,585
Accrued compensation	2,111,858	2,205,612	1,648,064
Deferred credits	404,487	691,424	832,822
Total current liabilities	6,441,408	7,206,390	6,931,659
Accrued liabilities - other	375,328	207,451
Long-term debt obligation	0	625,000	2,125,000
Long-term capital lease obligation	57,662	110,307	128,917
Total liabilities	6,499,070	7,941,697	9,185,576
Commitments and contingencies
Stockholders' equity:
Preferred stock, value	1,322	1,322	1,322
Common stock, value	15,387	14,842	14,245
Less treasury stock at cost, 22,725 shares at September 30, 2014 and zero at December 31, 2013	-32,221	0
Additional paid-in capital	63,824,535	62,756,571	61,361,505
Accumulated deficit	-44,213,835	-51,010,357	-50,104,880
Total stockholders' equity	19,595,188	11,762,378	11,272,192
Total liabilities and stockholders' equity	26,094,258	19,704,075	20,457,768
Scenario, Previously Reported
Current Liabilities:
Accrued liabilities		1,219,650	863,214
Accrued liabilities - other		$121,323	$235,897

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Preferred stock, shares authorized	1,321,514	1,321,514	1,321,514
Preferred stock, shares issued	1,321,514	1,321,514	1,321,514
Preferred stock, shares outstanding	1,321,514	1,321,514	1,321,514
Common stock, par value (in dollars per share)	$0.00	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	15,049,698	14,527,335	14,009,280
Common stock, shares outstanding	15,026,973	14,527,335	14,009,280
Treasury stock, shares	22,725	0

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
Consolidated Statements of Operations (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Technology development revenues	$3,067,022	$3,130,206	$8,961,909	$8,564,743	$11,421,868	$15,126,834
Products and licensing revenues	2,303,508	1,568,646	6,108,799	5,070,441	6,911,707	8,338,967
Total revenues	5,370,530	4,698,852	15,070,708	13,635,184	18,333,575	23,465,801
Cost of revenues:
Technology development costs	2,379,105	2,282,061	6,793,061	6,676,133	8,882,071	10,749,335
Products and licensing costs	908,175	739,646	2,654,305	2,322,776	3,402,846	3,824,661
Total cost of revenues	3,287,280	3,021,707	9,447,366	8,998,909	12,284,917	14,573,996
Gross profit	2,083,250	1,677,145	5,623,342	4,636,275	6,048,658	8,891,805
Operating expense:
Selling, general & administrative	2,329,713	2,447,972	7,551,512	7,986,541	10,970,775	10,249,444
Research, development and engineering	473,527	531,185	1,707,190	1,932,966	3,113,193	2,772,438
Total operating expense	2,803,240	2,979,157	9,258,702	9,919,507	14,083,968	13,021,882
Operating loss	-719,990	-1,302,012	-3,635,360	-5,283,232	-8,035,310	-4,130,077
Other income (expense):
Other income, net	0	78,162	111,431	271,306	347,026	108,061
Interest expense, net	-21,275	-42,654	-80,942	-150,614	-207,538	-312,372
Total other (expense) income	-21,275	35,508	30,489	120,692	139,488	-204,311
Loss from continuing operations before income taxes	-741,265	-1,266,504	-3,604,871	-5,162,540	-7,895,822	-4,334,388
Income tax benefit	-274,709	-491,925	-1,419,882	-2,033,694	-2,387,422	-1,106,564
Net loss from continuing operations	-466,556	-774,579	-2,184,989	-3,128,846	-5,508,400	-3,227,824
Operating (loss)/income from discontinued operations, net income taxes	-52	394,556	-28,127	900,179	1,313,611	1,843,439
(Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes	-277,562	-233,889	9,093,268	3,448,270	3,391,451	0
(Loss)/income from discontinued operations, net of income taxes	-277,614	160,667	9,065,141	4,348,449	4,705,250	1,843,439
Net (loss)/income	-744,170	-613,912	6,880,152	1,219,603	-803,150	-1,384,385
Preferred stock dividend	26,760	26,166	83,630	76,161	102,327	119,754
Net (loss)/income attributable to common stockholders	($770,930)	($640,078)	$6,796,522	$1,143,442	($905,477)	($1,504,139)
Net loss per share from continuing operations:
Basic	($0.03)	($0.05)	($0.15)	($0.22)	($0.38)	($0.23)
Diluted	($0.03)	($0.05)	($0.15)	($0.22)	($0.38)	($0.23)
Net (loss)/income per share from discontinued operations:
Basic	($0.02)	$0.01	$0.61	$0.30	$0.33	$0.13
Diluted	($0.02)	$0.01	$0.61	$0.30	$0.33	$0.13
Net (loss)/income per share attributable to common stockholders:
Basic	($0.05)	($0.04)	$0.46	$0.08	($0.06)	($0.11)
Diluted	($0.05)	($0.04)	$0.46	$0.08	($0.06)	($0.11)
Weighted average common shares and common equivalent shares outstanding:
Basic and Diluted	15,016,429	14,441,707	14,821,619	14,285,829	14,336,135	13,930,267

Consolidated_Statements_of_Ope1

Consolidated Statements of Operations (Parenthetical) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Income from discontinued operations, income taxes					$2,400,000	$1,100,000
Operating income (loss) from discontinued operations, tax	52	255,905	-18,077	590,181	879,819	1,127,981
Gain on sale, related income taxes	$300,000	$200,000	$1,600,000	$1,500,000	$1,500,000

Consolidated_Statements_Of_Cha

Consolidated Statements Of Changes In Stockholders' Equity (Deficit) (USD $)	Total	Preferred stock	Common Stock	Additional Paid in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2011	$10,704,066	$1,322	$13,969	$59,289,516	($48,600,741)
Begging balance (in shares) at Dec. 31, 2011		1,321,514	13,812,490
Exercise of stock options and warrants (in shares)			182,702
Exercise of stock options and warrants	69,978		183	69,795
Stock-based compensation	1,862,533			1,862,533
Stock dividends			79	119,675	-119,754
Issuance of Common Stock, Other	20,000		14	19,986
Issuance of Common Stock, Other (in shares)			14,088
Net (loss)/income	-1,384,385				-1,384,385
Ending Balance at Dec. 31, 2012	11,272,192	1,322	14,245	61,361,505	-50,104,880
Ending balance (in shares) at Dec. 31, 2012		1,321,514	14,009,280
Exercise of stock options and warrants (in shares)			169,277
Exercise of stock options and warrants	111,957		168	111,789
Stock-based compensation	1,166,379		338	1,166,041
Stock-based compensation (in shares)			337,500
Stock dividends			80	102,247	-102,327
Issuance of Common Stock, Other	15,000		11	14,989
Issuance of Common Stock, Other (in shares)			11,278
Net (loss)/income	-803,150				-803,150
Ending Balance at Dec. 31, 2013	$11,762,378	$1,322	$14,842	$62,756,571	($51,010,357)
Ending balance (in shares) at Dec. 31, 2013		1,321,514	14,527,335

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	9 Months Ended		12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Cash flows provided by/(used in) operating activities:
Net (loss)/income	$6,880,152	$1,219,603	($803,150)	($1,384,385)
Adjustments to reconcile net income (loss) to net cash provided/(used in) by operating activities:
Depreciation and amortization	491,066	711,375	935,477	1,092,027
Share-based compensation	738,802	896,554	1,181,379	1,882,533
Gain on sale of discontinued operations, net of income taxes	-9,093,268	-3,448,270	-3,391,451	0
Allowance for doubtful accounts or bad debt expense		124,810	134,811
Tax benefit from utilization of loss from current year operations	-1,437,958	-1,448,260	-1,507,791
Change in assets and liabilities
Accounts receivable	139,950	1,880,545	1,533,827	-1,101,549
Inventory	-92,320	-438,592	-9,261	-10,482
Other current assets	-170,857	26,931
Other assets	40,715	91,376	-79,180	478,919
Accounts payable and accrued expenses	-98,920	-600,471	396,352	-724,050
Deferred credits	-286,937	-274,746	-178,305	-629,781
Net cash provided by/(used in) operating activities	-2,889,575	-1,259,145	-1,787,292	-396,768
Cash flows (used in)/provided by investing activities:
Acquisition of property and equipment	-199,532	-161,519	-186,956	-371,390
Intangible property costs	-197,683	-187,928	-253,451	-224,537
Proceeds from sale of discontinued operations, net of fees	10,927,268	4,522,460	5,110,855
Net cash (used in)/provided by investing activities	10,530,053	4,173,013	4,670,448	-595,927
Cash flows (used in)/provided by financing activities
Payments on capital lease obligation	-49,587	-40,993	-57,033	-50,949
Payment of debt obligations	-1,125,000	-1,125,000	-1,500,000	-1,625,000
Purchase of treasury stock	-32,221
Proceeds from the exercise of options and warrants	217,945	96,329	111,957	69,978
Net cash used in financing activities	-988,863	-1,069,664	-1,445,076	-1,605,971
Net increase in cash and cash equivalents	6,651,615	1,844,204	1,438,080	-2,598,666
Cash and cash equivalents-beginning of period	7,778,541	6,340,461	6,340,461	8,939,127
Cash and cash equivalents-end of period	14,430,156	8,184,665	7,778,541	6,340,461
Supplemental disclosure of cash flow information
Cash paid for interest	73,917	142,188	178,646	297,875
Dividend on preferred stock	83,631	76,161	102,327	119,754
Cash paid for income taxes	$150,000	$14,010	$14,010	$21,618

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical)	9 Months Ended		12 Months Ended
Consolidated Statements of Cash Flows (Parenthetical)	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Statement of Cash Flows [Abstract]
Dividend on preferred stock, shares of common stock issuable	59,469	59,469	79,292	79,292
Dividend on preferred stock, shares of common stock issuable	0	0

Organization_and_Summary_of_Si

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	1. Organization and Summary of Significant Accounting Policies

	Luna Innovations Incorporated (“We” or the “Company”), headquartered in Roanoke, Virginia was incorporated in the Commonwealth of Virginia in 1990 and reincorporated in the State of Delaware in April 2003.

	We develop, manufacture and market fiber optic sensing and test & measurement products focused on bringing new and innovative technology solutions to measure, monitor, protect and improve critical processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. Our business model is designed to accelerate the process of bringing new and innovative products to market. We use our in-house technical expertise to perform applied research services on government-funded projects across a range of technologies and also for corporate customers in the fiber optic sensing area. We are organized into two business segments: our Technology Development segment and our Products and Licensing segment. Our Technology Development segment performs applied research principally on government-funded projects. Most of the government funding in our Technology Development segment is derived from the U.S. Government’s Small Business Innovation Research, or SBIR, program coordinated by the U.S. Small Business Administration, or SBA. Our Products and Licensing segment focuses on fiber optic test and measurement, sensing, and instrumentation products.

	We have a history of net losses and negative cash flow from operations. We have historically managed our liquidity through cost reduction initiatives, debt financings and capital markets transactions.

	Although there can be no guarantees, we believe that our current cash balance, including the proceeds from the sale of our medical shape sensing business to Intuitive in January 2014 described in Note 15, our cash flow from operations, and the funds available to us under the Credit Facility described in Note 3 below, provide adequate liquidity for us to meet our working capital needs through 2014.

	Discontinued Operations

	The Company’s Board of Directors and management determined that it would be in the best interest of the Company’s stockholders to sell the Secure Computing and Communication (“SCC”) group, which was part of the Technology Development segment, and medical shape sensing shape sensing business, which was part of the Product and Licensing Segment. On March 1, 2013, we completed the sale of our SCC for approximately $6.1 million. On January 21, 2014 we sold our assets associated with the medical shape sensing business for approximately $30.0 million.

	As a result, the Company has classified the operating results, net of taxes, of the aforementioned businesses as discontinued operations. The accompanying consolidated balance sheets of the Company as of December 31, 2012 and 2013, and the related consolidated statements of operations and cash flows for each of the two years in the period ended December 31, 2013, and the related notes to the consolidated financial statements have been retrospectively revised to reflect the classification of discontinued operations for these businesses. See Note 15, Discontinued Operations for further information. Unless otherwise noted, the following notes refer to the Company’s continuing operations.

	Consolidation Policy

	Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States, or GAAP and include the accounts of the Company and its wholly owned subsidiaries. We eliminate from our financial results all significant intercompany transactions. We do not have any investments in entities we believe are variable interest entities for which the Company is the primary beneficiary.



	Preferred Stock Issued to Carilion Clinic

	In January 2010, we entered into a transaction with Carilion Clinic (“Carilion”), in which Carilion agreed to exchange all of its Senior Convertible Promissory Notes in the principal amount of $5.0 million plus all accrued but unpaid interest, totaling $1.2 million, for (i) 1,321,514 shares of our newly designated Series A Convertible Preferred Stock and (ii) an additional warrant to purchase 356,000 shares of our common stock at an exercise price of $2.50 per share. This warrant is exercisable until December 31, 2020. We also agreed to reduce the exercise price of Carilion’s prior common stock warrant from $7.98 to $2.50 per share and to extend its expiration date to December 31, 2020. The Series A Convertible Preferred Stock carries a dividend of 6% payable in shares of common stock and maintains a liquidation preference up to $6.2 million. As of December 31, 2013, a cumulative total of 314,525 shares of common stock were issuable to Carilion, on their demand, as dividends and have been recorded in the statement of stockholders’ equity. Each share of Series A Convertible Preferred Stock may be converted into one share of our common stock at the option of the holder. We recorded the fair value of the Series A Convertible Preferred Stock, determined based upon the conversion value immediately prior to the exchange, the fair value of the new warrant issued, determined using the Black-Scholes valuation model, and the incremental fair value of the prior warrant due to the re-pricing and extension of expiration to stockholders’ equity.

	Use of Estimates

	The preparation of our consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes.

	Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may differ from such estimates and assumptions.

	Technology Development Revenues

	We perform research and development for U.S. government agencies, educational institutions and commercial organizations. We recognize revenues under research contracts when a contract has been executed, the contract price is fixed and determinable, delivery of services or products has occurred and collection of the contract price is considered reasonably assured. Revenue is earned under cost reimbursable, time and materials and fixed price contracts. Direct contract costs are expensed as incurred.

	Under cost reimbursable contracts, we are reimbursed for costs that are determined to be reasonable, allowable and allocable to the contract and are paid a fixed fee representing the profit negotiated between us and the contracting agency. Revenue from cost reimbursable contracts is recognized as costs are incurred plus a portion of the fee earned. Revenue from time and materials contracts is recognized based on direct labor hours expended at contract billing rates plus other billable direct costs.

	Revenue from fixed price research contracts that involve the delivery of services and a prototype model is recognized under the percentage of completion method. Fixed price arrangements that involve the delivery of research reports are recognized under the proportional performance method based upon the ratio of costs incurred to achieve contract milestones to total estimated cost as this method more accurately measures performance under these arrangements. Losses on contracts, if any, are recognized in the period in which they become known.

	Intellectual Property License Revenues

	Amounts received from third parties for licenses to our intellectual property are recognized when earned under the terms of the agreements. Revenues are recognized upon transfer of the license unless we have continuing obligations for which fair value cannot be established, in which case the revenues are recognized over the period of the obligation. If there are extended payment terms, license fee revenues are recognized as these payments become due and collection is reasonably assured. We consider all arrangements with payment terms extending beyond 12 months not to be fixed and determinable.

	Certain of our license arrangements have also required us to enter into research and development agreements. Accordingly, we allocate our arrangement fees to the various elements based upon objective reliable evidence of fair value, if available. For those arrangements in which evidence of fair value is not available, we defer revenues from any up-front payments and recognize them over the service period in the arrangement. Certain of these arrangements also include the payment of performance bonuses based upon the achievement of specific milestones. Generally, there are no assurances at the onset of these arrangements that the milestones will be achieved. As such, fees related to such milestones are excluded from the initial allocation of the arrangement fee and are recognized upon achievement of the milestone provided that all other revenue recognition criteria are met.

	Product Sales Revenues

	Revenues from product sales are generated by the sale of commercial products and services under various sales programs to the end user and through distribution channels. We sell fiber optic sensing systems to end users for use in numerous fiber optic based measurement applications. Revenues are recorded net of applicable sales taxes collected from customers and payable to state or local governmental entities.

	We recognize revenue relating to our products when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable and collectability of the resulting receivable is reasonably assured.

	For multi-element arrangements that include tangible products that contain software that is essential to the tangible product’s functionality, we allocate revenue to all deliverables based on their relative selling prices. Other deliverables include extended warranty, training and various add-on products. In such circumstances, we use a hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence of fair value or VSOE, (ii) third-party evidence of selling price or TPE, and (iii) best estimate of the selling price or ESP. VSOE generally exists only when we sell the deliverable separately and is the price actually charged by us for that deliverable. ESPs reflect our best estimates of what the selling prices of elements would be if they were sold regularly on a stand-alone basis.

	Our process for determining our ESP for deliverables without VSOE or TPE considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable. Key factors considered in developing the ESPs include prices charged by us for similar offerings, our historical pricing practices, the nature of the deliverables, and the relative ESP of all of the deliverables as compared to the total selling price of the product. We may also consider, when appropriate, the impact of other products and services on selling price assumptions when developing and reviewing our ESPs.

	Revenues from product sales that require no ongoing obligations are recognized as revenues when shipped to the customer, title has passed and collection is reasonably assured. In transactions in which a right-of-return exists, revenues are deferred until acceptance has occurred and the period for the right-of-return has lapsed.

	Allowance for Uncollectible Receivables

	Accounts receivable are recorded at their face amount, less an allowance for doubtful accounts. We review the status of our uncollected receivables on a regular basis. In determining the need for an allowance for uncollectible receivables, we consider our customers’ financial stability, past payment history and other factors that bear on the ultimate collection of such amounts. The allowance was $0 at December 31, 2012 and approximately $134,811 at December 31, 2013.



Cash Equivalents

We consider all highly liquid investments purchased with maturities of three months or less to be cash equivalents. To date, we have not incurred losses related to cash and cash equivalents. The Company regularly maintains cash balances with financial institutions which exceed Federal Deposit Insurance Corporation (“FDIC”) insurance limits. At December 31, 2013 and December 31, 2012, the Company had approximately $7.5 million and $6.1 million, respectively, in excess of FDIC insured limits.

Fair Value Measurements

The Company’s financial assets and liabilities are measured at fair value, which is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. Valuation techniques are based on observable or unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:


	•		Level 1—Quoted prices for identical instruments in active markets.


	•		Level 2—Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant value drivers are observable.


	•		Level 3—Valuations derived from valuation techniques in which significant value drivers are unobservable.

The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these instruments. The carrying value of the promissory notes approximate fair value as the interest rate is comparable to the interest rate on our credit facility with Silicon Valley Bank, which we consider to be at market.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation. We record depreciation using the straight-line method over the following estimated useful lives:



Equipment		3 – 7 years
Furniture and fixtures		7 years
Software		3 years
Leasehold improvements		Lesser of lease term or life of improvements

Intangible Assets

Intangible assets consist of patents related to certain intellectual property that we have developed or acquired. We amortize our patents over their estimated useful life of five years, and analyze them whenever events or circumstances indicate that the carrying amount may not be recoverable to determine whether their carrying value has been impaired.

Research, Development and Engineering

Research, development and engineering expenses not related to contract performance are expensed as incurred. We expensed $2.8 million and $3.1 million of non-contract related research, development and engineering expenses for the years ended December 31, 2012 and 2013, respectively.



Valuation of Long-Lived Assets

We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets is measured by comparing the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. Assets to be disposed of by sale are reflected at the lower of their carrying amount or fair value less cost to sell.

Inventory

Inventory consists of finished goods, work in process and parts valued at the lower of cost (determined on the first-in, first-out basis) or market. We provide reserves for estimated obsolescence or unmarketable inventory equal to the difference between the carrying value of the inventory and the estimated market value based upon assumptions about future demand and market conditions.

Net Loss per Share

Basic per share data is computed by dividing net loss attributable to common stockholders by the weighted average number of shares outstanding during the period. Diluted per share data is computed by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period increased to include, if dilutive, the number of additional common share equivalents that would have been outstanding if potential common shares had been issued using the treasury stock method. Diluted per share data would also include the potential common share equivalents relating to convertible securities by application of the if-converted method.

The effect of 2.4 million and 2.3 million common stock equivalents (which include outstanding warrants and stock options) are not included for the years ended December 31, 2012 and 2013 respectively, as they are antidilutive to earnings per share due to the Company’s loss from continuing operations.

Stock-Based Compensation

We have a stock-based compensation plan, which is described further in Note 8. We recognize compensation expense based upon the fair value of the underlying equity award as of the date of grant. The Company has elected to use the Black-Scholes option pricing model to value any awards granted. We amortize stock-based compensation for such awards on a straight-line method over the requisite service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior.

The Company recognizes expense for equity instruments issued to non-employees based upon the fair value of the equity instruments issued.

The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:



		2012		2013
Risk-free interest rate range		1.02% – 1.49%		1.27% – 2.34%
Expected life of option-years		7.5		7.5
Expected stock price volatility		108%		108%
Executive turnover rates		— %		— %
Non-executive turnover rates		18.50%		14.70%
Expected dividend yield		—		—



The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average volatility of our common stock. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executes, within our company. We do not currently issue dividends nor do we expect to in the foreseeable future.

Advertising

We expense the cost of advertising as incurred. Historically such amounts have not been significant to our operations.

Income Taxes

We account for income taxes using the liability method. Deferred tax assets or liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when the differences reverse. A valuation allowance against net deferred tax assets is provided unless we conclude it is more likely than not that the deferred tax assets will be realized.

We recognize tax benefits from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities.

Inventory

Inventory	9 Months Ended					12 Months Ended
Inventory	Sep. 30, 2014					Dec. 31, 2013
Inventory Disclosure [Abstract]
Inventory	3. Inventory					2. Inventory
	Inventory consists of finished goods, work-in-process and parts valued at the lower of cost (determined on the first-in, first-out basis) or market. We provide reserves for estimated obsolescence or unmarketable inventory equal to the difference between the cost of the inventory and the estimated market value based upon assumptions about future demand and market conditions.					Inventory consists of finished goods, work-in-process and parts valued at the lower of cost (determined on the first-in, first-out basis) or market. We provide reserves for estimated obsolescence or unmarketable inventory equal to the difference between the cost of the inventory and the estimated market value based upon assumptions about future demand and market conditions.
	Components of inventory are as follows:					Components of inventory are as follows:


		September 30,		December 31,			December 31,		December 31,
		2014		2013			2012		2013
	Finished goods	$	637,054	$	719,574	Finished goods	$	195,578	$	719,574
	Work-in-process		452,304		361,754	Work-in-process		252,227		361,754
	Parts		2,518,037		2,339,595	Parts		2,975,297		2,339,595

			3,607,395		3,420,923			3,423,102		3,420,923
	Less: Inventory reserves		207,263		74,746	Less: Inventory reserves		86,186		74,746

	Total inventory, net	$	3,400,132	$	3,346,177	Total inventory, net	$	3,336,916	$	3,346,177

Debt

Debt	9 Months Ended	12 Months Ended
Debt	Sep. 30, 2014	Dec. 31, 2013
Debt Disclosure [Abstract]
Debt	5. Debt	3. Debt
	Silicon Valley Bank Credit Facilities	Silicon Valley Bank Facility
	We currently have a Loan and Security Agreement with Silicon Valley Bank (“SVB”) in which we have a term loan with an original borrowing amount of $6.0 million (the “Term Loan”). The Term Loan is to be repaid by us in 48 monthly installments, plus accrued interest payable monthly in arrears, and unless earlier terminated, matures on the earlier of either May 1, 2015 or an event of a default under the loan agreement. The Term Loan carries a floating annual interest rate equal to SVB’s prime rate then in effect plus 2%, which is currently 6%. We may repay amounts due under the Term Loan at any time with no penalties.	We currently have a Loan and Security Agreement with Silicon Valley Bank (“SVB”) under which we have a term loan with an original borrowing amount of $6.0 million (the “Term Loan”). The Term Loan is to be repaid by us in 48 monthly installments, plus accrued interest payable monthly in arrears, and unless earlier terminated, matures on the earlier of either May 1, 2015 or an event of a default under the loan agreement. The term loan carries a floating annual interest rate equal to SVB’s prime rate then in effect plus 2%. We may repay amounts due under the Term Loan at any time with no penalties.
	In addition to the terms and conditions of the Term Loan, the loan and security agreement also previously included a revolving credit facility (the “Line of Credit”) with a maximum borrowing capacity of $1.0 million. The interest rate on the Line of Credit was SVB’s prime rate plus 1.25%, payable monthly in arrears, and we were required to pay an unused Line of Credit fee of one-quarter of one percent (0.25%), payable monthly. The Line of Credit had a maturity date of May 17, 2014, and we did not renew the Line of Credit upon its maturity.	In addition to the terms and conditions of the Term Loan, we also have a revolving credit facility (the “Line of Credit” and together with the Term Loan, the “Credit Facilities”) with a maximum borrowing capacity of $1.0 million. The interest rate on the Line of Credit is SVB’s prime rate plus 1.25%, payable monthly in arrears, and we are required to pay an unused Line of Credit fee of one-quarter of one percent (0.25%), payable monthly. We may terminate the Line of Credit for a termination fee of $10,000, which fee would not be payable in the event that the Line of Credit is replaced by another loan facility with SVB. The Line of Credit has a maturity date of May 18, 2014.
	Amounts due under the Term Loan are secured by substantially all of our assets, including intellectual property, personal property and bank accounts.	Amounts due under the Credit Facilities are secured by substantially all of our assets, including intellectual property, personal property and bank accounts.
	On March 21, 2013, we entered into a Fourth Loan Modification Agreement with SVB that replaced the existing financial covenants with a single covenant that we maintain a minimum cash balance of $5.0 million with SVB. Effective on January 21, 2014, in connection with our sale of our medical shape sensing business, this covenant was modified to reduce the required minimum cash balance to $3.0 million. The Term Loan also requires us to observe a number of operational covenants, including protection and registration of intellectual property rights, and certain customary negative covenants. As of September 30, 2014, we were in compliance with all covenants under the Term Loan.	On March 21, 2013, we entered into a Fourth Loan Modification Agreement with SVB that replaced the existing financial covenants with a single covenant that we maintain a minimum cash balance of $5.0 million with SVB. Effective on January 21, 2014, in connection with our sale of assets to Intuitive, this covenant was modified to reduce the required minimum cash balance to $3.5 million. The Credit Facilities also require us to observe a number of operational covenants, including protection and registration of intellectual property rights, and certain customary negative covenants. As of December 31, 2013, we were in compliance with all covenants under the Credit Facilities.
	In addition, the Term Loan contains customary events of default, including nonpayment of principal, interest or other amounts, violation of covenants, material adverse change, an event of default under any subordinated debt documents, incorrectness of representations and warranties in any material respect, bankruptcy, judgments in excess of a threshold amount, and violations of other agreements in excess of a threshold amount. If any event of default occurs SVB may declare due immediately all borrowings under the Term Loan and foreclose on the collateral. Furthermore, an event of default under the Term Loan would result in an increase in the interest rate on any amounts outstanding. As of September 30, 2014, there were no events of default on our Term Loan.	In addition, the Credit Facilities contain customary events of default, including nonpayment of principal, interest or other amounts, violation of covenants, material adverse change, an event of default under any subordinated debt documents, incorrectness of representations and warranties in any material respect, bankruptcy, judgments in excess of a threshold amount, and violations of other agreements in excess of a threshold amount. If any event of default occurs SVB may declare due immediately all borrowings under the Credit Facilities and foreclose on the collateral. Furthermore, an event of default under the Credit Facilities would result in an increase in the interest rate on any amounts outstanding. As of December 31, 2013, there were no events of default on our Credit Facilities.
	On October 15, 2014 we applied for a letter of credit in the amount of $500,000 with SVB, to be provided in connection with our new Blacksburg, Virginia lease, effective October 1, 2014.	The balance under the Term Loan at December 31, 2013 was $2.1 million of which $0.6 million was classified as long-term and $1.5 million was classified as short-term. No amounts were outstanding under the Line of Credit and the available credit capacity was $1.0 million at December 31, 2013. The effective rate of our Term Loan at December 31, 2013 was 6%.
		The following table presents a summary of debt outstanding as of December 31, 2012 and 2013:
	The balance under the Term Loan at September 30, 2014, was $1.0 million, all of which was classified as short-term.

			December 31,
			2012		2013
		Silicon Valley Bank Term Loan	$	3,625,000	$	2,125,000

		Less: current portion		1,500,000		1,500,000

		Total long-term debt	$	2,125,000	$	625,000

		Maturities on long-term debt are as follows:


		Year	Amount
		2014		1,500,000
		2015		625,000

		Total	$	2,125,000


		Costs associated with loans outstanding were as follows:


			Years Ended December 31,
			2012		2013
		Interest expense	$	286,529	$	189,151
		Amortization of transaction costs		25,843		18,387

		Total interest expense	$	312,372	$	207,538

Accounts_ReceivableTrade

Accounts Receivable-Trade	12 Months Ended
Accounts Receivable-Trade	Dec. 31, 2013
Receivables [Abstract]
Accounts Receivable-Trade	4. Accounts Receivable—Trade
	Accounts receivable consist of the following:


		December 31,
		2012		2013
	Billed	$	5,175,395	$	3,552,184
	Unbilled		1,873,376		1,755,439
	Other		10,864		235,469

		$	7,059,635	$	5,543,092

	Less: allowance for doubtful accounts		—		(134,811	)

		$	7,059,635	$	5,408,281

	Unbilled receivables result from contract retainages and revenues that have been earned in advance of billing and can be invoiced at contractually defined intervals, milestones, or at completion of the contract.
	Unbilled amounts are expected to be billed in future periods and are classified as current assets in accordance with industry practice.

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Property and Equipment	5. Property and Equipment
	Property and equipment, net, consists of the following at:


		December 31,
		2012			2013
	Building	$	69,556		$	69,556
	Equipment		7,222,208			7,239,017
	Furniture and fixtures		622,944			562,485
	Software		1,185,290			1,092,484
	Leasehold improvements		3,196,590			3,168,377

			12,296,588			12,131,919
	Less—accumulated depreciation		(9,869,950	)		(10,071,210	)

		$	2,426,638		$	2,060,709

	Depreciation for the years ended December 31, 2012 and 2013 was approximately $0.8 million and $0.5 million, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	6. Intangible Assets
	The following is a summary of intangible assets:


		December 31,
		2012			2013
	Patent costs	$	2,264,441		$	2,496,560
	Accumulated amortization		(1,826,602	)		(2,208,085	)

		$	437,839		$	288,475

	Amortization for the years ended December 31, 2012 and 2013 was approximately $0.3 million and $0.4 million, respectively. Estimated aggregate amortization, based on the net value of intangible assets at December 31, 2013, for each of the next five years is as follows:


	Year Ending December 31,
	2014		188,616
	2015		53,371
	2016		24,844
	2017		10,578
	2018		6,013

		$	283,422

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Income Taxes	7. Income Taxes
	Deferred tax assets and liabilities consist of the following components:


		2012						2013
		Current			Long-Term			Current			Long-Term
	Bad debt and inventory reserve	$	41,243		$	—		$	88,077		$	—
	Deferred revenue		—			—			—			59,673
	Depreciation and amortization		—			1,005,697			—			1,024,784
	Net operating loss carryforwards		—			11,358,044			—			10,896,286
	Research and development credits		—			386,161			—			386,161
	Accrued liabilities		731,831			—			836,011			—
	Deferred compensation		—			123,797			—			163,655
	Stock-based compensation		—			1,208,970			—			1,519,513
	AMT credit		—			28,555			—			42,711

	Total		773,074			14,111,224			924,088			14,092,783
	Valuation allowance		(773,074	)		(14,111,224	)		(924,088	)		(14,092,783	)

	Net deferred tax asset	$	—		$	—		$	—		$	—

	The reconciliation of expected income tax benefit (expense) to actual income tax expense benefit (expense) was as follows:


		2012			2013
	Statutory federal rate		34	%		34	%
	State tax net of federal benefit		3.73	%		3.96	%
	Change in valuation allowance		(4.16	)%		(16.88	)%
	Incentive stock options		(35.60	)%		(41.60	)%
	Provision to return adjustments		(1.80	)%		24.11	%
	Meals and entertainment		(0.74	)%		(1.33	)%
	Other Permanent differences		(0.60	)%		(4.37	)%

	Income tax (expense)		(5.17	)%		(2.11	)%


	The income tax expense consists of the following for:


		2012			2013
	Current:
	Federal	$	18,268		$	14,071
	State		3,149			—
	Deferred Federal		—			—
	Deferred State		—			—

	Income tax expense	$	21,417		$	14,071

	The realization of our deferred income tax assets is dependent upon sufficient taxable income in future periods. In assessing whether deferred tax assets may be realized, we consider whether it is more likely than not that some portion, or all, of the deferred tax asset will be realized. We consider scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategies that we can implement in making our assessment. We have net operating loss carryforwards at December 31, 2013 of approximately $28.7 million expiring at varying dates through 2025. We have research and development tax credit carryforwards at December 31, 2013 of approximately $0.4 million, which expire at varying dates through 2024.
	We have undertaken a formal section 382 study and determined that we do not have a limitation on our net operating loss available to offset income.
	The U.S. federal statute of limitations remains open for the year 2005 and onward. We currently have no federal income tax returns under examination. U.S. state jurisdictions have statutes of limitation generally ranging from three to seven years. We currently have no state income or franchise tax returns under examination. We currently do not file tax returns in any foreign tax jurisdiction.
	We currently have no positions for which we expect that the amount of unrecognized tax benefit will increase or decrease significantly within twelve months of the reporting date. We have no tax interest or penalties reported in either our statement of operations or statement of financial position for any year reported herein. Management believes it is not more likely than not that the deferred tax assets at December 31, 2012 or December 31, 2013 will be realized, and therefore a valuation allowance was established against all such deferred tax assets.
	We are evaluating the potential impact of the final Treasury regulations released on September 13, 2013 concerning amounts paid to acquire, produce or improve tangible property and recovery of basis upon disposition. We are determining whether or not any changes in accounting method will be required and if they will result in a material impact to our financial statements. At this time, we do not anticipate there being a material impact.
	Windfall equity-based compensation deductions are tracked, but will not be recorded to the balance sheet until management determines it is more likely than not that such amounts will be utilized. As of December 31, 2013, the Company had approximately $165,000 of windfall stock compensation deductions. If and when realized, the tax benefit associated with these deductions will be credited to additional paid-in capital. These excess benefit deductions are included in the total federal net operating losses disclosed above.

Capital_Stock_and_Additional_P

Capital Stock and Additional Paid-in Capital	9 Months Ended																		12 Months Ended
Capital Stock and Additional Paid-in Capital	Sep. 30, 2014																		Dec. 31, 2013
Equity [Abstract]
Capital Stock and Additional Paid-in Capital	6. Capital Stock and Additional Paid-in Capital																		8. Stockholders’ Equity
	The following details our equity transactions during the nine months ended September 30, 2014:																		Series A Convertible Preferred Stock
																			In January 2010, we entered into a transaction with Carilion, in which Carilion agreed to exchange all of its Senior Convertible Promissory Notes in the principal amount of $5.0 million plus all accrued but unpaid interest, totaling $1.2 million, for 1,321,514 shares of our newly designated Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock is non-voting, carries a dividend of 6% payable in shares of common stock and maintains a liquidation preference up to $6.2 million. As of December 31, 2013, 314,525 shares of common stock were issuable to Carilion as dividends and have been recorded in the statement of stockholders’ equity. These dividends are issuable on demand. Each share of Series A Convertible Preferred Stock may be converted into one share of our common stock at the option of the holder. We recorded the fair value of the Series A Convertible Preferred Stock, determined based upon the conversion value immediately prior to the exchange, the fair value of the new warrant issued to Carilion (as described below), determined using the Black-Scholes valuation model, and the incremental fair value of the prior warrant due to the re-pricing (as described below) and extension of maturity to stockholders’ equity.
																			Hansen Warrant
			Preferred Stock				Common Stock				Treasury Stock						Additional		In January 2010, we issued 1,247,330 shares of common stock to Hansen, representing 9.9% of our common stock then outstanding. In addition, we issued to Hansen a warrant entitling Hansen to purchase a number of shares of our common stock as necessary for Hansen to maintain a 9.9% ownership interest in our common stock, at an exercise price of $0.01 per share. During 2012, Hansen did not exercise any of its outstanding warrants. During 2013, Hansen exercised warrants acquiring an additional 32,180 shares. The warrant expired on January 12, 2013 in accordance with its terms. For the years ended December 31, 2012 and 2013, we recognized expense of $17,190 and $0, respectively, which is included in operating expenses. We recognized expense based upon the fair market value of our stock at the date the shares were issuable, updated quarterly for non-exercised warrants, to Hansen.
																	Paid-in		Stock Option Plans
																	Capital		In April 2003, we adopted the Luna Innovations Incorporated 2003 Stock Plan, or the 2003 Plan. Under the 2003 Plan, our Board of Directors was authorized to grant both incentive and non-statutory stock options to our employees, directors and consultants to purchase Class B shares of Common Stock. Options generally had a life of 10 years and exercise price equal to or greater than the fair market value of the Class B Common Stock as determined by the Board of Directors. On February 4, 2006, our Board of Directors increased the number of shares reserved under the 2003 Plan to 9,715,000. There were options outstanding under the 2003 Plan to purchase an aggregate of 945,472 shares as of December 31, 2013. Following the adoption of the 2006 Equity Incentive Plan in January 2006, no shares or options are available for future grant under the 2003 Plan, except to satisfy grants outstanding as of June 5, 2006.
			Shares		$		Shares		$		Shares			$			$		In January 2006, we adopted our 2006 Equity Incentive Plan or the 2006 Plan. Under the 2006 Plan, our Board of Directors is authorized to grant both incentive and non-statutory stock options to purchase common stock and restricted stock awards to our employees, directors, and consultants. Stock option awards generally have a life of 10 years and exercise prices equal to the closing price of our common stock on the date of the option grant. On January 1 of each year, the number of shares available for issuance increases by the lesser of (a) 10% of the outstanding shares of our common stock on the last day of the preceding fiscal year; (b) 1,695,690 shares; or (c) such other amount as our Board of Directors may determine. A total of 8,872,540 and 10,468,175 shares were available for future grant under the 2006 Plan as of December 31, 2012 and 2013, respectively.
	Balances, December 31, 2013			1,321,514		1,322		14,527,335		14,842		—			—			62,756,571	Vesting for employees typically occurs over a five-year period.
	Exercise of stock options			—		—		276,586		277		—			—			217,668	Total non-cash stock option expense for the years ended December 31, 2012 and 2013 was $1.9 million and $1.2 million, respectively.
	Share-based compensation			—		—		268,500		209		—			—			766,724
	Stock dividends to Carilion Clinic (1)			—		—		—		59		—			—			83,572	The following table sets forth the activity of the options to purchase common stock under the 2003 Plan and the 2006 Plan:
	Purchase of treasury stock											(22,725	)		(32,221	)

	Balances, September 30, 2014			1,321,514		1,322		15,072,421		15,387		(22,725	)		(32,221	)		63,824,535			Options Outstanding							Options Exercisable
																					Number of			Price per		Weighted		Aggregate		Number		Weighted		Aggregate
																					Shares			Share		Average		Intrinsic		of		Average		Intrinsic
	-1	The stock dividends payable in connection with Carilion Clinic’s Series A Preferred Stock will be issued subsequent to September 30, 2014. For the period from January 12, 2010, the original issue date of the Series A Preferred Stock, through September 30, 2014, the Series A Preferred Stock issued to Carilion has accrued $793,807 in dividends. The accrued and unpaid dividends as of September 30, 2014 will be paid by the issuance of 373,994 shares of our common stock upon Carilion’s written request.																						Range		Exercise		Value (1)		Shares		Exercise		Value (1)
																										Price						Price
																			Balance at January 1, 2012			4,641,039		$	0.35–6.74	$	2.23	$	1,509,270		3,206,994	$	2.23	$	1,258,740
																			Forfeited			(64,245	)		0.65–5.50		1.91
																			Exercised			(182,702	)		0.35–1.77		0.38
																			Granted			1,028,038			1.40–1.75		1.67

																			Balance at December 31, 2012			5,422,130		$	0.35–6.74	$	2.19	$	639,904		3,775,388	$	2.37	$	604,292
																			Forfeited			(693,644	)		0.35–6.74		2.08
																			Exercised			(137,097	)		0.35–1.18		0.56
																			Granted			687,840			1.20–1.31		1.29

																			Balance at December 31, 2013			5,279,229		$	0.35–6.55	$	2.11	$	784,154		4,012,378	$	2.28	$	697,826


																			-1	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-money options only. The prices represent the closing price of our Common Stock on the NASDAQ Capital Market on the respective dates.


																								Options Outstanding						Options Exercisable
																					Range of			Options		Weighted		Weighted		Options		Weighted
																					Exercise Prices			Outstanding		Average		Average		Exercisable		Average
																										Remaining		Exercise				Exercise
																										Life in		Price				Price of
																										Years						Options
																																Exercisable
																			Year ended December 31, 2012		$	0.35–6.74			5,422,130		6.39	$	2.19		3,775,388	$	2.37
																			Year ended December 31, 2013		$	0.35–6.55			5,279,229		5.88	$	2.11		4,012,378	$	2.28


																					Total intrinsic value of			Total fair value of
																					options exercised			options vested
																			Year ended December 31, 2012		$	215,541		$	1,170,738
																			Year ended December 31, 2013		$	111,595		$	1,248,067
																			For the years ended December 31, 2012 and 2013, the weighted average grant date fair value of options granted was $1.10 and $1.29, respectively. We estimate the fair value of options at the grant date using the Black-Scholes model.
																			We will recognize $1.6 million over the remaining requisite service period. For all options granted through December 31, 2013, the weighted average remaining service period is 1.7 years.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended	12 Months Ended
Commitments and Contingencies	Sep. 30, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Contingencies and Guarantees	9. Commitments and Contingencies
	We are from time to time involved in certain legal proceedings in the ordinary course of conducting our business. While the ultimate liability pursuant to these actions cannot currently be determined, we believe these legal proceedings will not have a material adverse effect on our financial position or results of operations.	Obligation under Operating Leases
	In the fourth quarter of 2013 we executed two non-cancelable purchase orders totaling $1.4 million for multiple shipments of tunable lasers to be delivered over an 18-month period beginning in 2013. At September 30, 2014, approximately $0.7 million of this commitment remained.	We lease facilities in Blacksburg, Charlottesville and Roanoke, Virginia under operating leases that as of December 31, 2013, were scheduled to expire between November 2014 and December 2018. Certain of the leases are subject to fixed escalations and provide for possible termination prior to their expiration dates. We recognize rent expense on such leases on a straight-line basis over the lease term. Rent expense under these leases recorded in our selling, general and administrative expense line on our statement of operations totaled approximately $1.3 million and $1.0 million, respectively, for the years ended December 31, 2012 and 2013. During 2013, we subleased a portion of the office space formerly occupied by Secure Computing and Communications group (“SCC”) to Mac-B. The amount of the sublease income recognized in 2013 was approximately $266,000. The sublease continues through April 30, 2014.

	In September 2014, we received a preliminary audit report from the Defense Contract Audit Agency, or DCAA, with respect to our 2007 incurred cost submission and questioning $0.8 million of claimed costs that the DCAA believes are expressly unallowable under the Federal Acquisition Regulations and, therefore, subject to potential penalty. We have not been informed of any actual claim for penalty by the Defense Contract Management Agency and intend to contest such claim if received.	We are obligated under operating leases covering certain equipment that expire at various dates during the next two years.
	We have entered into indemnification agreements with our officers and directors, to the extent permitted by law, pursuant to which we have agreed to reimburse the officers and directors for legal expenses in the event of litigation and regulatory matters. The terms of these indemnification agreements provide for no limitation to the maximum potential future payments. We have a directors and officers insurance policy that may, in certain instances, mitigate the potential liability and payments.	Minimum future rentals, as of December 31, 2013, under the aforementioned operating leases for each of the next five years are:


		2014		1,014,131
		2015		503,760
		2016		299,635
		2017		305,628
		2018		311,740

			$	2,434,894

		Purchase Commitment
		In the fourth quarter of 2013 we executed two non-cancelable purchase orders totaling $1.4 million for multiple shipments of tunable lasers to be delivered over an 18-month period beginning in the fourth quarter of 2013. At December 31, 2013, approximately $1.4 million of this commitment remained.
		Royalty Agreement
		We have licensed certain third-party technologies from vendors for which we owe minimum royalties aggregating $1.8 million payable over the remaining patent terms of the underlying technology.

Employee_Profit_Sharing_Plan

Employee Profit Sharing Plan	12 Months Ended
Employee Profit Sharing Plan	Dec. 31, 2013
Compensation and Retirement Disclosure [Abstract]
Employee Profit Sharing Plan	10. Employee Profit Sharing Plan
	We maintain a salary reduction/profit-sharing plan under provisions of Section 401(k) of the Internal Revenue Code. The plan is offered to employees who have completed three months of service with us. We contribute 25% of the salary deferral elected by each employee up to a maximum deferral of 10% of annual salary.
	We contributed approximately $250,000 and $175,000 to the plan for the years ended December 31, 2012 and 2013, respectively.

Litigation_and_Other_Contingen

Litigation and Other Contingencies	12 Months Ended
Litigation and Other Contingencies	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Litigation and Other Contingencies	11. Litigation and Other Contingencies
	From time to time, we may become involved in litigation in relation to claims arising out of our operations in the normal course of business. While management currently believes the amount of ultimate liability, if any, with respect to these actions will not materially affect our financial position, results of operations or liquidity, the ultimate outcome of any litigation is uncertain.
	We have made, and will continue to make, efforts to comply with current and future environmental laws. We anticipate that we could incur additional capital and operating costs in the future to comply with existing environmental laws and new requirements arising from new or amended statutes and regulations. In addition, because the applicable regulatory agencies have not yet promulgated final standards for some existing environmental programs, we cannot at this time reasonably estimate the cost for compliance with these additional requirements. The amount of any such compliance costs could be material. We cannot predict the impact that future regulations will impose upon our business.

Relationship_with_Major_Custom

Relationship with Major Customers	12 Months Ended
Relationship with Major Customers	Dec. 31, 2013
Relationshipwith Major Customers [Abstract]
Relationship with Major Customers	12. Relationship with Major Customers
	During the years ended December 31, 2012 and 2013, approximately 66% and 64%, respectively, of our consolidated revenues were attributable to contracts with the U.S. government.

	At December 31, 2012 and 2013, receivables with respect to contracts with the U.S. government represented 34% and 25% of total billed trade receivables, respectively.

Financial_Information_About_Se

Financial Information About Segments	9 Months Ended													12 Months Ended
Financial Information About Segments	Sep. 30, 2014													Dec. 31, 2013
Segment Reporting [Abstract]
Financial Information About Segments	7. Operating Segments													13. Financial Information About Segments
	Our operations are divided into two operating segments—“Technology Development” and “Products and Licensing”.
	The Technology Development segment provides applied research to customers in our areas of focus. Our engineers and scientists collaborate with our network of government, academic and industry experts to identify technologies and ideas with promising market potential. We then compete to win fee-for-service contracts from government agencies and industrial customers who seek innovative solutions to practical problems that require new technology. The Technology Development segment derives its revenues primarily from services.													Our operations are divided into two operating segments: Technology Development and Products and Licensing. The Technology Development segment provides applied research to customers in our areas of focus.
	The Products and Licensing segment derives its revenues from product sales, funded product development and technology licenses. This segment previously included our medical shape sensing business, which was sold on January 21, 2014, and the amounts below do not include the revenues, expenses and assets of our medical shape sensing business.
	Through September 30, 2014, our Chief Executive Officer and his direct reports collectively represented our chief operating decision makers, and they evaluated segment performance based primarily on revenues and operating income or loss. The accounting policies of our segments are the same as those described in the summary of significant accounting policies (see Note 1 to our Financial Statements, “Organization and Summary of Significant Accounting Policies,” presented in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission on April 10, 2014 and amended on April 15, 2014).													Our engineers and scientists collaborate with our network of government, academic and industry experts to identify technologies and ideas with promising market potential. We then compete to win fee-for-service contracts from government agencies and industrial customers who seek innovative solutions to practical problems that require new technology. The Technology Development segment derives its revenue primarily from services.

	The table below presents revenues and operating loss for reportable segments not including discontinued operations:													The Products and Licensing segment develops and sells products or licenses technologies based on commercially viable concepts developed by the Technology Development segment. The Products and Licensing segment derives its revenue from product sales, funded product development and technology licenses.

														Our President and Chief Executive Officer and his direct reports collectively represent our chief operating decision makers, and they evaluate segment performance based primarily on revenue and operating income or loss.
		Three Months Ended						Nine Months Ended
		September 30,						September 30,						Information about the results of operations for each segment is set forth in the table below. There were no significant inter-segment sales during the two years ended December 31, 2013. There was an insignificant amount of product sales made outside the United States during these two years.
		2014			2013			2014			2013
		(unaudited)						(unaudited)
	Revenues:
	Technology development revenues	$	3,067,022		$	3,130,206		$	8,961,909		$	8,564,743			Year Ended December 31,
	Products and licensing revenues		2,303,508			1,568,646			6,108,799			5,070,441			2012			2013
														Technology Development revenue	$	15,126,834		$	11,421,868
	Total revenues	$	5,370,530		$	4,698,852		$	15,070,708		$	13,635,184		Products and Licensing revenue		8,338,967			6,911,707

	Technology development operating loss	$	(299,980	)	$	(259,486	)	$	(2,835,120	)	$	(599,303	)	Total revenue		23,465,801			18,333,575
	Products and licensing operating loss		(420,010	)		(1,042,526	)		(800,240	)		(4,683,929	)
														Technology Development operating loss		(1,703,370	)		(3,169,605	)
	Total operating loss	$	(719,990	)	$	(1,302,012	)	$	(3,635,360	)	$	(5,283,232	)	Products and Licensing operating loss		(2,426,707	)		(4,865,705	)

	Depreciation, technology development	$	49,592		$	86,413		$	160,327		$	272,570		Total operating loss from continuing operations		(4,130,077	)	$	(8,035,310	)
	Depreciation, products and licensing	$	37,247		$	43,304		$	109,037		$	161,426
	Amortization, technology development	$	38,641		$	61,563		$	131,615		$	173,140		Depreciation, Technology Development	$	499,439		$	286,894
	Amortization, products and licensing	$	29,022		$	30,851		$	90,087		$	104,239		Depreciation, Products and Licensing		266,327			266,862
	The table below presents assets for reportable segments:													Amortization, Technology Development		212,790			197,765
														Amortization, Products and Licensing		113,471			183,956

		September 30,			December 31,									Additional segment information is as follows:
		2014			2013
	Total segment assets:
	Technology development	$	14,902,005		$	10,208,433
	Products and licensing		11,192,253			9,495,642									December 31,
															2012			2013
	Total	$	26,094,258		$	19,704,075								Total segment assets:
														Technology Development	$	13,342,725		$	10,208,433
	Property plant and equipment, and intangible assets, technology development	$	1,198,066		$	1,217,083								Products and Licensing		7,115,043			9,495,642
	Property plant and equipment, and intangible assets, products and licensing	$	899,816		$	1,132,101
	There are no material inter-segment revenues for any period presented.													Total	$	20,457,768		$	19,704,075
	The United States Government accounted for approximately 60% and 62% of total consolidated revenues for the three months ended September 30, 2014 and 2013, respectively, and 60% and 56% of total consolidated revenues for the nine months ended September 30, 2014 and 2013, respectively.
	International revenues (customers outside the United States) accounted for approximately 15% and 16% of total consolidated revenues for the three months ended September 30, 2014 and 2013, respectively, and 16% and 23% of total consolidated revenues for the nine months ended September 30, 2014 and 2013, respectively.													Property plant and equipment and intangible assets, Technology Development	$	1,868,235		$	1,217,083
														Property plant and equipment and intangible assets, Products and Licensing	$	996,242		$	1,132,101

Quarterly_Results_unaudited

Quarterly Results (unaudited)	12 Months Ended
Quarterly Results (unaudited)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Quarterly Results (unaudited)	14. Quarterly Results (unaudited)

	The following table sets forth our unaudited historical revenues, operating loss and net (loss) income by quarter during 2012 and 2013.



		Quarter Ended
	(Dollars in thousands,	March 31,			June 30,			September 30,			December 31,			March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012			2013			2013			2013			2013
	except per share amounts)
	Revenues:
	Technology	$	3,943		$	3,895		$	3,691		$	3,598		$	2,627		$	2,807		$	3,130		$	2,858
	Products and licensing		2,338			1.993			2,021			1,986			1,478			2,024			1,569			1,841

	Total revenues		6,281			5,888			5,712			5,584			4,105			4,831			4,699			4,699
	Gross Margin		2,533			2,315			2,266			1,778			1,135			1,777			1,677			1,460
	Operating loss		(867	)		(922	)		(1,020	)		(1,322	)		(2,241	)		(1,739	)		(1,302	)		(2,753	)
	Loss from continuing operations, net		(712	)		(681	)		(759	)		(1,076	)		(1,319	)		(1,035	)		(775	)		(2,379	)
	Income/(loss) from discontinued operations net of income taxes		378			438			539			489			4,105			83			161			356
	Net income/(loss)		(334	)		(243	)		(220	)		(587	)		2,786			(952	)		(614	)		(2,023	)
	Net (loss)/income attributable to common stockholders	$	(369	)	$	(269	)	$	(254	)	$	(612	)	$	2,762		$	(978	)	$	(640	)	$	(2,049	)

	Net loss per share from continuing operations:
	Basic	$	(0.05	)	$	(0.05	)	$	(0.05	)	$	(0.08	)	$	(0.09	)	$	(0.07	)	$	(0.05	)	$	(0.16	)
	Diluted	$	(0.05	)	$	(0.05	)	$	(0.05	)	$	(0.08	)	$	(0.09	)	$	(0.07	)	$	(0.05	)	$	(0.16	)
	Net income/(loss) per share from discontinued operations:
	Basic	$	0.03		$	0.03		$	0.04		$	0.03		$	0.29		$	0.01		$	0.01		$	0.03
	Diluted	$	0.03		$	0.03		$	0.04		$	0.03		$	0.29		$	0.01		$	0.01		$	0.03
	Net (loss)/income attributable to common stockholders:
	Basic	$	(0.03	)	$	(0.02	)	$	(0.02	)	$	(0.04	)	$	0.2		$	(0.07	)	$	(0.04	)	$	(0.14	)
	Diluted	$	(0.03	)	$	(0.02	)	$	(0.02	)	$	(0.04	)	$	0.2		$	(0.07	)	$	(0.04	)	$	(0.14	)
	Weighted average shares:
	Basic and Diluted		13,850,667			13,892,816			13,939,938			14,008,772			14,011,814			14,362,494			14,441,707			14,488,060

Discontinued_Operations

Discontinued Operations	9 Months Ended												12 Months Ended
Discontinued Operations	Sep. 30, 2014												Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	2. Discontinued Operations												15. Discontinued Operations
													On March 1, 2013, we completed the sale of our SCC which was part of our Technology Development segment, to an unaffiliated third party for a gross sales price of $6.1 million of cash. Prior to the sale, SCC provided innovative solutions designed to secure critical technologies within the U.S. government. SCC conducted applied research and provided services to the government in this area, with its revenues primarily derived from U.S. government contracts and purchase orders. Of the purchase price, we received approximately $5.4 million at closing and $110,000 on December 31, 2013. During December 2013, an additional $475,000 in purchase price was released to us from escrow and another $125,000 is in escrow and may be released 18 months, after the closing of the transaction, subject to any indemnification claims of the acquirer. In connection with the sale, we incurred approximately $0.9 million in transaction costs that included various charges related to investment banker and legal fees. In addition, the acquirer has entered into a sublease with us for the facilities historically occupied by SCC through April 30, 2014 for a total of $0.4 million. In the transaction, we sold the equipment, contracts and intellectual property associated with SCC. Approximately 20 employees of SCC transferred to the acquirer. Included in the transaction were current assets of approximately $0.2 million and long term assets with a net book value of approximately $0.1 million, at February 28, 2013. SCC accounted for 18.5% of our revenues, and 20.7% of our cost of revenues for the year ended December 31, 2012. We recorded an aggregate after-tax gain on the sale of SCC of $3.3 million or $0.20 per diluted share in our results of operations for the year ended December 31, 2013.
	On March 1, 2013, we completed the sale of our Secure Computing and Communications group (“SCC”), which was part of our Technology Development segment, to an unaffiliated third party for a gross sales price of $6.1 million of cash. Prior to the sale, SCC provided innovative solutions designed to secure critical technologies within the U.S. government. SCC conducted applied research and provided services to the government in this area, with its revenues primarily derived from U.S. government contracts and purchase orders. Of the purchase price, we received approximately $5.4 million at closing and $110,000 on December 31, 2013. During December 2013, an additional $475,000 in purchase price was released to us from escrow and the remaining $125,000 was released to us in October 2014. In connection with the sale, we incurred approximately $0.9 million in transaction costs that included various charges related to investment banker and legal fees. In addition, the acquirer entered into a sublease with us for the facilities historically occupied by SCC through April 30, 2014 for a total of $106,000 for the nine months ended September 30, 2014. In the transaction, we sold the equipment, contracts and intellectual property associated with SCC. Approximately 20 employees of SCC transferred to the acquirer. Included in the transaction were current assets of approximately $0.2 million and long term assets with a net book value of approximately $0.1 million, at February 28, 2013. We recorded an aggregate after-tax gain on the sale of SCC of $3.3 million or $0.23 per diluted share in our results of operations for the year ended December 31, 2013.												Following the sale of SCC, we have continued to act on behalf of the purchaser and bill the government for certain contracts that have not yet been transferred by the government to the purchaser. We record this activity within (loss)/income from discontinued operations. During the year ended December 31, 2013, this amount was $1.7 million. We expect to continue recording such activity until all of these contracts are transferred to the purchaser by the government.
													The operating income from discontinued operations for the year ended December 31, 2013, is the result the allocation of the alternative minimum tax computation on the company’s results as a whole at December 31, 2013.
	We have reported the results of operations of SCC as discontinued operations in our consolidated financial statements. We allocated a portion of the consolidated tax expense to discontinued operations based on the ratio of the discontinued group’s income or loss before allocations. Through December 31, 2013, we continued to act on behalf of the purchaser and bill the government for certain contracts that have not yet been transferred by the government to the purchaser. We recorded these amounts as revenues, with an offsetting amount as cost of revenues, within (loss)/income from discontinued operations.												On January 21, 2014, we sold our assets associated with the development of fiber optic shape sensing and localization for the medical field to affiliates of Intuitive Surgical, Inc., for total cash consideration of up to $30 million, including $6 million received at closing, and $6 million to be received within 90 days of closing, and up to $18 million that may be received in the future based on the achievement of certain technical milestones and royalties on system sales, if any. In the transaction, we sold equipment and intellectual property associated with our shape sensing technology. Ten employees were transferred to Intuitive. Included in the transaction were current assets of totaling approximately $0.2 million and long term assets with a net book value of approximately $0.2 million, at December 31, 2013. Our fiber optic shape sensing and localization for the medical field accounted for approximately 12% of our revenues, and 9% of our cost of revenues for the year ended December 31, 2013.
													We have reported the results of operations of SCC and our shape sensing business as discontinued operations in our consolidated financial statements. We allocated a portion of the consolidated tax expense to discontinued operations based on the ratio of the discontinued group’s income or loss before allocations.
	On January 21, 2014, we completed the sale of our medical shape sensing business, which was part of our Products and Licensing segment, to an unaffiliated third party for a gross sales price of up to $30.0 million, of which $12.0 million in cash has been received, up to $8.0 million is payable to us in the future upon the accomplishment by the buyer of certain technical specifications, and we may receive up to $10.0 million in potential future royalties. We had been engaged since 2007 in various development projects developing a fiber optic-based shape sensing and position tracking system to be integrated in the buyer’s products. Also as part of the transaction, the buyer has hired certain employees of the company, many of whom were historically engaged in this development project. In connection with this sale, we incurred approximately $1.3 million in transaction costs that included various charges related to investment banker and legal fees and a bonus to a former employee who was hired by the buyer. Included in the transaction were current and long term assets with a net book value of approximately $0.3 million on January 20, 2014. Our medical shape sensing business accounted for 12% of our revenues and 10% of our costs of revenues for the year ended December 31, 2013. We recorded an after-tax loss on the sale of medical shape sensing business of $0.3 million, or $0.02 per diluted share, for the three months ended September 30, 2014, due to intraperiod allocation of income taxes in the third quarter of 2014 and an after-tax gain of $9.1 million, or $0.61 per diluted share, for the nine months ended September 30, 2014.												The key components of income/ (loss) from discontinued operations were as follows:

	We have reported the results of operations of SCC and our medical shape sensing business as discontinued operations in our consolidated financial statements. We allocated a portion of the consolidated tax expense to discontinued operations based on the ratio of the discontinued groups’ income before allocations.
														Year Ended December 31,
	The key components of income from discontinued operations were as follows:													2012		2013
													Net revenues	$	8,883,202	$	5,909,375
													Cost of revenues		5,337,336		3,486,200
													Operating expenses		574,446		229,745
		Three Months Ended						Nine Months Ended
		September 30, 2014			September 30, 2013			September 30, 2014			September 30, 2013		Income/(loss) before income taxes		2,971,420		2,193,430
	Net revenues	$	—		$	1,578,308		$	—		$	4,343,391	Allocated tax expense/(benefit)		1,127,981		879,819
	Cost of revenues		—			927,847			46,204			2,623,286
	Operating expenses		—			—			—			229,745	Operating income/(loss) from discontinued operations		1,843,439		1,313,611
													Gain on sale, net of $1.5 million of related income taxes		—		3,391,639
	Income/(loss) before income taxes		—			650,461			(46,204	)		1,490,360
	Allocated tax expense/(benefit)		52			255,905			(18,077	)		590,181	Income from discontinued operations, net of income taxes ($1.0 million and $2.4 million, respectively)	$	1,843,439	$	4,705,250

	Operating (loss)/income from discontinued operations, net of income taxes		(52	)		394,556			(28,127	)		900,179
	(Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes		(277,562	)		(233,889	)		9,093,268			3,448,270

	(Loss)/income from discontinued operations, net of income taxes	$	(277,614	)	$	160,667		$	9,065,141		$	4,348,449

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	9 Months Ended
Basis of Presentation and Significant Accounting Policies	Sep. 30, 2014
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies

	Nature of Operations

	Luna Innovations Incorporated (“we,” “Luna Innovations” or the “Company”) is incorporated in the State of Delaware and headquartered in Roanoke, Virginia. We develop, manufacture and market fiber optic sensing, test and measurement products and are focused on bringing new and innovative technology solutions to measure, monitor, protect and improve critical processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. We are organized into two main groups, which work closely together to turn ideas into products: our Technology Development segment and our Products and Licensing segment. Our business model is designed to accelerate the process of bringing new and innovative technologies to market. We have a history of net losses from continuing operations from 2005 through the nine months ended September 30, 2014. We have historically managed our liquidity through cost reduction initiatives, debt financings, capital market transactions and asset sales.

	Since the second half of 2008, the increased turmoil in the U.S. and global capital markets and a global slowdown of economic growth created a substantially more difficult business environment. Our ability to access the capital markets may be limited. Economic and market conditions may not improve significantly during the remainder of 2014 and could get worse.

	Although there can be no guarantees, we believe that our current cash balance will provide adequate liquidity for us to meet our working capital needs over the next twelve months.

	Unaudited Interim Financial Information

	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Act of 1934. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. The unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments, consisting of only normal recurring accruals considered necessary to present fairly our financial position at September 30, 2014, results of operations for the three and nine months ended September 30, 2014 and 2013, and cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.

	The consolidated interim financial statements, including our significant accounting policies, should be read in conjunction with the audited Consolidated Financial Statements and the notes thereto for the year ended December 31, 2013, included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on April 10, 2014 and amended on April 15, 2014.

	Consolidation Policy

	Our consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and our wholly owned subsidiaries. We have eliminated from our financial results all significant intercompany transactions. We do not have any investments in entities we believe are variable interest entities for which we are the primary beneficiary.



	Fair Value Measurements

	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between marketplace participants. Various valuation approaches can be used to determine fair value, each requiring different valuation inputs. The following hierarchy classifies the inputs used to determine fair value into three levels:


		•		Level 1—Quoted prices for identical instruments in active markets


		•		Level 2—Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets


		•		Level 3—Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable

	The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these instruments. The carrying value of our debt approximates fair value, as we consider the floating interest rate on our credit facilities with Silicon Valley Bank to be at market. Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis in accordance with U.S. GAAP. This includes items such as nonfinancial assets and liabilities initially measured at fair value in a business combination and nonfinancial long-lived asset groups measured at fair value for an impairment assessment. In general, nonfinancial assets including intangible assets and property and equipment are measured at fair value when there is an indication of impairment and are recorded at fair value only when any impairment is recognized.

	Use of Estimates

	The preparation of our consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may differ from such estimates and assumptions.



	Earnings Per Share



			Net loss per share from continuing																Net (loss)/income attributable to common
			operations																stockholders
			For the three months								For the nine months								For the three months								For the nine months
			ended September 30,								ended September 30,								ended September 30,								ended September 30,
			2014				2013				2014				2013				2014				2013				2014			2013
	Numerator:
	Net loss from continuing operations		$	(466,556	)		$	(774,579	)		$	(2,184,989	)		$	(3,128,846	)
	Net (loss)/income attributable to stockholders																		$	(770,930	)		$	(640,078	)		$	6,796,522		$	1,143,442
	Denominator:
	Basic weighted average common shares outstanding			15,016,429				14,441,707				14,821,619				14,285,829				15,016,429				14,441,707				14,821,619			14,285,829
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards			—				—				—				—				—				—				—			—
	Convertible preferred stock			—				—				—				—				—				—				—			—
	Preferred stock dividends			—				—				—				—				—				—				—			—

	Diluted weighted average common shares outstanding			15,016,429				14,441,707				14,821,619				14,285,829				15,016,429				14,441,707				17,185,369			16,593,102
	Basic net loss per share from continuing operations		$	(0.03	)		$	(0.05	)		$	(0.15	)		$	(0.22	)
	Diluted net loss per share from continuing operations		$	(0.03	)		$	(0.05	)		$	(0.15	)		$	(0.22	)
Basic net (loss)/income per share attributable to common stockholders																		$	(0.05	)		$	(0.04	)		$	0.46		$	0.08
Diluted net (loss)/income per share attributable to common stockholders																		$	(0.05	)		$	(0.04	)		$	0.46		$	0.08

Weighted-average anti-dilutive shares related to:
Outstanding stock options			4,448,259				5,322,656				4,086,208				5,322,686				4,448,259				5,322,656				3,005,297			4,095,725
Convertible preferred stock			1,321,514				1,321,514				1,321,514				1,321,514				1,321,514				1,321,514				1,321,514			1,321,514
Preferred stock dividends			373,994				274,879				354,171				255,056				373,994				274,879				354,171			255,056
Restricted stock			330,160				261,257				290,394				219,759				330,160				261,257				290,394			219,759
Carilion warrants			366,000				366,000				366,000				366,000				366,000				366,000				366,000			366,000

The weighted-average anti-dilutive shares shown in the foregoing table were not included in the computation of diluted net loss from continuing operations and net income per share attributable to common stockholders. For reporting periods in which we have a net loss from continuing operations, the weighted-average anti-dilutive shares comprise shares that would have been dilutive had we had net income from continuing operations (e.g., convertible preferred stock, preferred stock dividends, restricted stock, warrants and stock options that have exercise prices below the average stock price for the period), plus the number of stock options that would be anti-dilutive had we had a net income from continuing operations.

Share-Based Compensation

We recognize share-based compensation expense based upon the fair value of the underlying equity award on the date of the grant. For restricted stock awards and restricted stock units, we recognize expense based upon the price of our underlying stock at the date of the grant. We have elected to use the Black-Scholes option pricing model to value any option or warrant awards granted. We amortize share-based compensation for such awards on a straight-line basis over the related service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior. To compute the volatility used in this model we use the historical volatility of our common stock over the expected life of options granted. The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups within our company. We also assume an expected dividend yield of zero for all periods, as we have never paid a dividend on our common stock and do not have any plans to do so in the future.

The fair value of each option granted during the nine months ended September 30, 2014 and 2013 was estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:



		Nine Months Ended				Nine Months Ended
		September 30, 2014				September 30, 2013
Risk-free interest rate			2.14	%			1.27 - 2.34	%
Expected life of options (in years)			7.5				7.5
Expected stock price volatility			106	%			108	%

A summary of the activity for our 2003 Stock Plan and 2006 Equity Incentive Plan is presented below for the nine months ended September 30, 2014:



		Options Outstanding																Options Exercisable
		Number of				Price per				Weighted				Aggregate				Number of				Weighted				Aggregate
		Shares				Share				Average				Intrinsic				Shares				Average				Intrinsic
						Range				Exercise				Value (1)								Exercise				Value (1)
										Price												Price
Balance, January 1, 2014			5,279,229			$	0.35 - $6.55			$	2.11			$	784,154				4,012,378			$	2.28			$	697,826
Granted			915,952			$	1.37 - $1.53			$	1.42
Exercised			(276,586	)		$	0.35 - $1.27			$	0.79
Canceled			(1,470,336	)		$	0.35 - $6.55			$	1.4

Balance, September 30, 2014			4,448,259			$	0.35 - $6.55			$	1.92			$	494,279				3,055,457			$	2.11			$	459,175



-1	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of Luna’s common stock on the NASDAQ Capital Market, as applicable, on the respective dates.

At September 30, 2014, the outstanding stock options to purchase an aggregate of 4.4 million shares had a weighted average remaining contractual term of 6.3 years, and the exercisable stock options to purchase an aggregate of 3.1 million shares had a weighted average remaining contractual term of 5.0 years.

For each of the three months ended September 30, 2014 and 2013, we recognized $0.3 million, and for the nine months ended September 30, 2014, and 2013, we recognized $0.7 million and $0.9 million, respectively, in share-based compensation expense, which is included in our selling, general and administrative expense in the accompanying consolidated financial statements. We expect to recognize $1.6 million in share-based compensation expense over the weighted average remaining service period of 1.6 years for stock options outstanding as of September 30, 2014.

During the nine months ended September 30, 2014, we repurchased 22,725 shares of common stock, at an average share price of $1.42 per share, pursuant to the election of the holders in order to satisfy tax withholding requirements with respect to the vesting of their respective restricted stock awards.

Intangible Assets and Other Long Lived Assets

Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair market value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair market value, less cost to sell.

Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

Accounting Renouncements

The FASB issued ASU 2014-09 “Revenue from Contracts with Customers” clarifying the method used to determine the timing and requirements for revenue recognition on the statements of income. Under the new standard, an entity must identify the performance obligations in a contract, the transaction price and allocate the price to specific performance obligations to recognize the revenue when the obligation is completed. The amendments in this update also require disclosure of sufficient information to allow users to understand the nature, amount, timing and uncertainty of revenue and cash flow arising from contracts. The new accounting guidance is effective for interim and annual periods beginning after December 15, 2016. Luna is analyzing the impact of this new standard and, at this time, cannot estimate the impact of adoption on revenue or net income. Luna plans to adopt ASU 2014-09 effective January 1, 2017.

Accrued_Liabilities

Accrued Liabilities	9 Months Ended
Accrued Liabilities	Sep. 30, 2014
Payables and Accruals [Abstract]
Accrued Liabilities	4. Accrued Liabilities


		September 30, 2014		December 31, 2013
	Accrued compensation	$	2,111,858	$	2,205,612
	Accrued sub-contracts		309,570		297,510
	Accrued professional fees		20,885		279,991
	Accrued income tax		162,105		13,143
	Deferred rent		72,477		102,569
	Royalties		344,383		291,442
	Warranty reserve		61,850		56,700
	Claims reserve		—		92,167
	Accrued liabilities—other		375,328		207,451

	Total Accrued Liabilities	$	3,458,456	$	3,546,585

Valuation_and_Qualifying_Accou

Valuation and Qualifying Accounts	12 Months Ended
Valuation and Qualifying Accounts	Dec. 31, 2013
Valuation and Qualifying Accounts [Abstract]
Valuation and Qualifying Accounts	Schedule II
	Luna Innovations Incorporated
	Valuation and Qualifying Accounts


	Column A	Column B		Column C		Column D			Column E		Column F
		Balance		Charged		Deductions			Valuation		Balance at
		at beginning		to costs					against		end
		of Period		and					asset		of period
				expenses
	Year Ended December 31, 2013
	Reserves deducted from assets to which they apply:
	Inventory obsolescence	$	86,186	$	—	$	(11,435	)	$	—	$	74,751
	Allowances for doubtful Accounts	$	—	$	134,811	$	—		$	—	$	134,811

		$	86,186	$	134,811	$	(11,435	)	$	—	$	209,562
	Year Ended December 31, 2012
	Reserves deducted from assets to which they apply:
	Inventory obsolescence	$	147,676	$	—	$	(61,490	)	$	—	$	86,186
	Allowances for doubtful Accounts	$	22,372	$	—	$	(22,372	)	$	—	$	—

		$	170,048	$	—	$	(83,862	)	$	—	$	86,186

Organization_and_Summary_of_Si1

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended																								12 Months Ended
	Sep. 30, 2014																								Dec. 31, 2013
Accounting Policies [Abstract]
Nature of Operations	Nature of Operations																								Luna Innovations Incorporated (“We” or the “Company”), headquartered in Roanoke, Virginia was incorporated in the Commonwealth of Virginia in 1990 and reincorporated in the State of Delaware in April 2003.
	Luna Innovations Incorporated (“we,” “Luna Innovations” or the “Company”) is incorporated in the State of Delaware and headquartered in Roanoke, Virginia. We develop, manufacture and market fiber optic sensing, test and measurement products and are focused on bringing new and innovative technology solutions to measure, monitor, protect and improve critical processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. We are organized into two main groups, which work closely together to turn ideas into products: our Technology Development segment and our Products and Licensing segment. Our business model is designed to accelerate the process of bringing new and innovative technologies to market. We have a history of net losses from continuing operations from 2005 through the nine months ended September 30, 2014. We have historically managed our liquidity through cost reduction initiatives, debt financings, capital market transactions and asset sales.																								We develop, manufacture and market fiber optic sensing and test & measurement products focused on bringing new and innovative technology solutions to measure, monitor, protect and improve critical processes in the aerospace, automotive, energy, composite, telecommunications and defense industries. Our business model is designed to accelerate the process of bringing new and innovative products to market. We use our in-house technical expertise to perform applied research services on government-funded projects across a range of technologies and also for corporate customers in the fiber optic sensing area. We are organized into two business segments: our Technology Development segment and our Products and Licensing segment. Our Technology Development segment performs applied research principally on government-funded projects. Most of the government funding in our Technology Development segment is derived from the U.S. Government’s Small Business Innovation Research, or SBIR, program coordinated by the U.S. Small Business Administration, or SBA. Our Products and Licensing segment focuses on fiber optic test and measurement, sensing, and instrumentation products.
	Since the second half of 2008, the increased turmoil in the U.S. and global capital markets and a global slowdown of economic growth created a substantially more difficult business environment. Our ability to access the capital markets may be limited. Economic and market conditions may not improve significantly during the remainder of 2014 and could get worse.																								We have a history of net losses and negative cash flow from operations. We have historically managed our liquidity through cost reduction initiatives, debt financings and capital markets transactions.
	Although there can be no guarantees, we believe that our current cash balance will provide adequate liquidity for us to meet our working capital needs over the next twelve months.																								Although there can be no guarantees, we believe that our current cash balance, including the proceeds from the sale of our medical shape sensing business to Intuitive in January 2014 described in Note 15, our cash flow from operations, and the funds available to us under the Credit Facility described in Note 3 below, provide adequate liquidity for us to meet our working capital needs through 2014.
Consolidation Policy	Consolidation Policy																								Consolidation Policy
Consolidation Policy	Our consolidated financial statements are prepared in accordance with U.S. GAAP and include the accounts of the Company and our wholly owned subsidiaries. We have eliminated from our financial results all significant intercompany transactions. We do not have any investments in entities we believe are variable interest entities for which we are the primary beneficiary.																								Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States, or GAAP and include the accounts of the Company and its wholly owned subsidiaries. We eliminate from our financial results all significant intercompany transactions. We do not have any investments in entities we believe are variable interest entities for which the Company is the primary beneficiary.
Use of Estimates	Use of Estimates																								Use of Estimates
	The preparation of our consolidated financial statements in accordance with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may differ from such estimates and assumptions.																								The preparation of our consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes.
																									Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may differ from such estimates and assumptions.
Technology Development Revenues																									Technology Development Revenues
																									We perform research and development for U.S. government agencies, educational institutions and commercial organizations. We recognize revenues under research contracts when a contract has been executed, the contract price is fixed and determinable, delivery of services or products has occurred and collection of the contract price is considered reasonably assured. Revenue is earned under cost reimbursable, time and materials and fixed price contracts. Direct contract costs are expensed as incurred.
																									Under cost reimbursable contracts, we are reimbursed for costs that are determined to be reasonable, allowable and allocable to the contract and are paid a fixed fee representing the profit negotiated between us and the contracting agency. Revenue from cost reimbursable contracts is recognized as costs are incurred plus a portion of the fee earned. Revenue from time and materials contracts is recognized based on direct labor hours expended at contract billing rates plus other billable direct costs.
																									Revenue from fixed price research contracts that involve the delivery of services and a prototype model is recognized under the percentage of completion method. Fixed price arrangements that involve the delivery of research reports are recognized under the proportional performance method based upon the ratio of costs incurred to achieve contract milestones to total estimated cost as this method more accurately measures performance under these arrangements. Losses on contracts, if any, are recognized in the period in which they become known.
Intellectual Property License Revenues																									Intellectual Property License Revenues
																									Amounts received from third parties for licenses to our intellectual property are recognized when earned under the terms of the agreements. Revenues are recognized upon transfer of the license unless we have continuing obligations for which fair value cannot be established, in which case the revenues are recognized over the period of the obligation. If there are extended payment terms, license fee revenues are recognized as these payments become due and collection is reasonably assured. We consider all arrangements with payment terms extending beyond 12 months not to be fixed and determinable.
																									Certain of our license arrangements have also required us to enter into research and development agreements. Accordingly, we allocate our arrangement fees to the various elements based upon objective reliable evidence of fair value, if available. For those arrangements in which evidence of fair value is not available, we defer revenues from any up-front payments and recognize them over the service period in the arrangement. Certain of these arrangements also include the payment of performance bonuses based upon the achievement of specific milestones. Generally, there are no assurances at the onset of these arrangements that the milestones will be achieved. As such, fees related to such milestones are excluded from the initial allocation of the arrangement fee and are recognized upon achievement of the milestone provided that all other revenue recognition criteria are met.
Product Sales Revenues																									Product Sales Revenues
																									Revenues from product sales are generated by the sale of commercial products and services under various sales programs to the end user and through distribution channels. We sell fiber optic sensing systems to end users for use in numerous fiber optic based measurement applications. Revenues are recorded net of applicable sales taxes collected from customers and payable to state or local governmental entities.
																									We recognize revenue relating to our products when persuasive evidence of an arrangement exists, delivery has occurred, the selling price is fixed or determinable and collectability of the resulting receivable is reasonably assured.
																									For multi-element arrangements that include tangible products that contain software that is essential to the tangible product’s functionality, we allocate revenue to all deliverables based on their relative selling prices. Other deliverables include extended warranty, training and various add-on products. In such circumstances, we use a hierarchy to determine the selling price to be used for allocating revenue to deliverables: (i) vendor-specific objective evidence of fair value or VSOE, (ii) third-party evidence of selling price or TPE, and (iii) best estimate of the selling price or ESP. VSOE generally exists only when we sell the deliverable separately and is the price actually charged by us for that deliverable. ESPs reflect our best estimates of what the selling prices of elements would be if they were sold regularly on a stand-alone basis.
																									Our process for determining our ESP for deliverables without VSOE or TPE considers multiple factors that may vary depending upon the unique facts and circumstances related to each deliverable. Key factors considered in developing the ESPs include prices charged by us for similar offerings, our historical pricing practices, the nature of the deliverables, and the relative ESP of all of the deliverables as compared to the total selling price of the product. We may also consider, when appropriate, the impact of other products and services on selling price assumptions when developing and reviewing our ESPs.
																									Revenues from product sales that require no ongoing obligations are recognized as revenues when shipped to the customer, title has passed and collection is reasonably assured. In transactions in which a right-of-return exists, revenues are deferred until acceptance has occurred and the period for the right-of-return has lapsed.
Allowance for Uncollectible Receivables																									Allowance for Uncollectible Receivables
Allowance for Uncollectible Receivables																									Accounts receivable are recorded at their face amount, less an allowance for doubtful accounts. We review the status of our uncollected receivables on a regular basis. In determining the need for an allowance for uncollectible receivables, we consider our customers’ financial stability, past payment history and other factors that bear on the ultimate collection of such amounts. The allowance was $0 at December 31, 2012 and approximately $134,811 at December 31, 2013.
Cash Equivalents																									Cash Equivalents
Cash Equivalents																									We consider all highly liquid investments purchased with maturities of three months or less to be cash equivalents. To date, we have not incurred losses related to cash and cash equivalents. The Company regularly maintains cash balances with financial institutions which exceed Federal Deposit Insurance Corporation (“FDIC”) insurance limits. At December 31, 2013 and December 31, 2012, the Company had approximately $7.5 million and $6.1 million, respectively, in excess of FDIC insured limits.
Fair Value Measurements	Fair Value Measurements																								Fair Value Measurements
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between marketplace participants. Various valuation approaches can be used to determine fair value, each requiring different valuation inputs. The following hierarchy classifies the inputs used to determine fair value into three levels:																								The Company’s financial assets and liabilities are measured at fair value, which is defined as the price that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants. Valuation techniques are based on observable or unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs have created the following fair value hierarchy:

		•		Level 1—Quoted prices for identical instruments in active markets																						•		Level 1—Quoted prices for identical instruments in active markets.

		•		Level 2—Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets																						•		Level 2—Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which significant value drivers are observable.

		•		Level 3—Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable																						•		Level 3—Valuations derived from valuation techniques in which significant value drivers are unobservable.
	The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these instruments. The carrying value of our debt approximates fair value, as we consider the floating interest rate on our credit facilities with Silicon Valley Bank to be at market. Certain nonfinancial assets and liabilities are measured at fair value on a nonrecurring basis in accordance with U.S. GAAP. This includes items such as nonfinancial assets and liabilities initially measured at fair value in a business combination and nonfinancial long-lived asset groups measured at fair value for an impairment assessment. In general, nonfinancial assets including intangible assets and property and equipment are measured at fair value when there is an indication of impairment and are recorded at fair value only when any impairment is recognized.																								The carrying values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value because of the short-term nature of these instruments. The carrying value of the promissory notes approximate fair value as the interest rate is comparable to the interest rate on our credit facility with Silicon Valley Bank, which we consider to be at market.
Property and Equipment																									Property and Equipment
																									Property and equipment are stated at cost less accumulated depreciation. We record depreciation using the straight-line method over the following estimated useful lives:


																									Equipment		3 – 7 years
																									Furniture and fixtures		7 years
																									Software		3 years
																									Leasehold improvements		Lesser of lease term or life of improvements
Intangible Assets	Intangible Assets and Other Long Lived Assets																								Intangible Assets
Intangible Assets	Long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset might not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair market value of the asset. Assets to be disposed of are reported at the lower of the carrying amount or fair market value, less cost to sell.																								Intangible assets consist of patents related to certain intellectual property that we have developed or acquired. We amortize our patents over their estimated useful life of five years, and analyze them whenever events or circumstances indicate that the carrying amount may not be recoverable to determine whether their carrying value has been impaired.
Research, Development and Engineering																									Research, Development and Engineering

																									Research, development and engineering expenses not related to contract performance are expensed as incurred. We expensed $2.8 million and $3.1 million of non-contract related research, development and engineering expenses for the years ended December 31, 2012 and 2013, respectively.
Valuation of Long-Lived Assets																									Valuation of Long-Lived Assets
Valuation of Long-Lived Assets																									We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets is measured by comparing the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds their fair value. Assets to be disposed of by sale are reflected at the lower of their carrying amount or fair value less cost to sell.
Inventory																									Inventory
Inventory																									Inventory consists of finished goods, work in process and parts valued at the lower of cost (determined on the first-in, first-out basis) or market. We provide reserves for estimated obsolescence or unmarketable inventory equal to the difference between the carrying value of the inventory and the estimated market value based upon assumptions about future demand and market conditions.
Earnings Per Share	Earnings Per Share																								Net Loss per Share

																									Basic per share data is computed by dividing net loss attributable to common stockholders by the weighted average number of shares outstanding during the period. Diluted per share data is computed by dividing net loss attributable to common stockholders by the weighted average shares outstanding during the period increased to include, if dilutive, the number of additional common share equivalents that would have been outstanding if potential common shares had been issued using the treasury stock method. Diluted per share data would also include the potential common share equivalents relating to convertible securities by application of the if-converted method.
			Net loss per share from continuing												Net (loss)/income attributable to common
			operations												stockholders										The effect of 2.4 million and 2.3 million common stock equivalents (which include outstanding warrants and stock options) are not included for the years ended December 31, 2012 and 2013 respectively, as they are antidilutive to earnings per share due to the Company’s loss from continuing operations.
			For the three months						For the nine months						For the three months						For the nine months
			ended September 30,						ended September 30,						ended September 30,						ended September 30,
			2014			2013			2014			2013			2014			2013			2014		2013
	Numerator:
	Net loss from continuing operations		$	(466,556	)	$	(774,579	)	$	(2,184,989	)	$	(3,128,846	)
	Net (loss)/income attributable to stockholders														$	(770,930	)	$	(640,078	)	$	6,796,522	$	1,143,442
	Denominator:
	Basic weighted average common shares outstanding			15,016,429			14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			14,821,619		14,285,829
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards			—			—			—			—			—			—			688,065		730,703
	Convertible preferred stock			—			—			—			—			—			—			1,321,514		1,321,514
	Preferred stock dividends			—			—			—			—			—			—			354,171		255,056

	Diluted weighted average common shares outstanding			15,016,429			14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			17,185,369		16,593,102
	Basic net loss per share from continuing operations		$	(0.03	)	$	(0.05	)	$	(0.15	)	$	(0.22	)
	Diluted net loss per share from continuing operations		$	(0.03	)	$	(0.05	)	$	(0.15	)	$	(0.22	)
	Basic net (loss)/income per share attributable to common stockholders														$	(0.05	)	$	(0.04	)	$	0.46	$	0.08
	Diluted net (loss)/income per share attributable to common stockholders														$	(0.05	)	$	(0.04	)	$	0.4	$	0.07

	Weighted-average anti-dilutive shares related to:
	Outstanding stock options			4,448,259			5,322,656			4,086,208			5,322,686			4,448,259			5,322,656			3,005,297		4,095,725
	Convertible preferred stock			1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			—		—
	Preferred stock dividends			373,994			274,879			354,171			255,056			373,994			274,879			—		—
	Restricted stock			330,160			261,257			290,394			219,759			330,160			261,257			—		—
	Carilion warrants			366,000			366,000			366,000			366,000			366,000			366,000			366,000		366,000
	The weighted-average anti-dilutive shares shown in the foregoing table were not included in the computation of diluted net loss from continuing operations and net income per share attributable to common stockholders. For reporting periods in which we have reported net income attributable to common stockholders, weighted-average anti-dilutive shares comprise stock options that have exercise prices above the average stock price for the period. For reporting periods in which we have a net loss from continuing operations, the weighted-average anti-dilutive shares comprise shares that would have been dilutive had we had net income from continuing operations (e.g., convertible preferred stock, preferred stock dividends, restricted stock, warrants and stock options that have exercise prices below the average stock price for the period), plus the number of stock options that would be anti-dilutive had we had a net income from continuing operations.
Share-Based Compensation	Share-Based Compensation																								Stock-Based Compensation
	We recognize share-based compensation expense based upon the fair value of the underlying equity award on the date of the grant. For restricted stock awards and restricted stock units, we recognize expense based upon the price of our underlying stock at the date of the grant. We have elected to use the Black-Scholes option pricing model to value any option or warrant awards granted. We amortize share-based compensation for such awards on a straight-line basis over the related service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior. To compute the volatility used in this model we use the historical volatility of our common stock over the expected life of options granted. The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups within our company. We also assume an expected dividend yield of zero for all periods, as we have never paid a dividend on our common stock and do not have any plans to do so in the future.																								We have a stock-based compensation plan, which is described further in Note 8. We recognize compensation expense based upon the fair value of the underlying equity award as of the date of grant. The Company has elected to use the Black-Scholes option pricing model to value any awards granted. We amortize stock-based compensation for such awards on a straight-line method over the requisite service period of the awards taking into account the effects of the employees’ expected exercise and post-vesting employment termination behavior.
	The fair value of each option granted during the nine months ended September 30, 2014 and 2013 was estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:																								The Company recognizes expense for equity instruments issued to non-employees based upon the fair value of the equity instruments issued.
																									The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:

			Nine Months Ended			Nine Months Ended
			September 30, 2014			September 30, 2013																					2012		2013
	Risk-free interest rate			2.14	%		1.27 - 2.34	%																	Risk-free interest rate range		1.02% – 1.49%		1.27% – 2.34%
	Expected life of options (in years)			7.5			7.5																		Expected life of option-years		7.5		7.5
	Expected stock price volatility			106	%		108	%																	Expected stock price volatility		108%		108%
	A summary of the activity for our 2003 Stock Plan and 2006 Equity Incentive Plan is presented below for the nine months ended September 30, 2014:																								Executive turnover rates		— %		— %
																									Non-executive turnover rates		18.50%		14.70%
																									Expected dividend yield		—		—
			Options Outstanding												Options Exercisable
			Number of			Price per			Weighted			Aggregate			Number of			Weighted			Aggregate				The risk-free interest rate is based on U.S. Treasury interest rates, the terms of which are consistent with the expected life of the stock options. Expected volatility is based upon the average volatility of our common stock. The expected life and estimated post-employment termination behavior is based upon historical experience of homogeneous groups, executives and non-executes, within our company. We do not currently issue dividends nor do we expect to in the foreseeable future.
			Shares			Share			Average			Intrinsic			Shares			Average			Intrinsic
						Range			Exercise			Value (1)						Exercise			Value (1)
									Price									Price
	Balance, January 1, 2014			5,279,229		$	0.35 - $6.55		$	2.11		$	784,154			4,012,378		$	2.28		$	697,826
	Granted			915,952		$	1.37 - $1.53		$	1.42
	Exercised			(276,586	)	$	0.35 - $1.27		$	0.79
	Canceled			(1,470,336	)	$	0.35 - $6.55		$	1.4

	Balance, September 30, 2014			4,448,259		$	0.35 - $6.55		$	1.92		$	494,279			3,055,457		$	2.11		$	459,175


	-1	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of Luna’s common stock on the NASDAQ Capital Market, as applicable, on the respective dates.
	At September 30, 2014, the outstanding stock options to purchase an aggregate of 4.4 million shares had a weighted average remaining contractual term of 6.3 years, and the exercisable stock options to purchase an aggregate of 3.1 million shares had a weighted average remaining contractual term of 5.0 years.
	For each of the three months ended September 30, 2014 and 2013, we recognized $0.3 million, and for the nine months ended September 30, 2014, and 2013, we recognized $0.7 million and $0.9 million, respectively, in share-based compensation expense, which is included in our selling, general and administrative expense in the accompanying consolidated financial statements. We expect to recognize $1.6 million in share-based compensation expense over the weighted average remaining service period of 1.6 years for stock options outstanding as of September 30, 2014.
	During the nine months ended September 30, 2014, we repurchased 22,725 shares of common stock, at an average share price of $1.42 per share, pursuant to the election of the holders in order to satisfy tax withholding requirements with respect to the vesting of their respective restricted stock awards.
Advertising																									Advertising
Advertising																									We expense the cost of advertising as incurred. Historically such amounts have not been significant to our operations.
Income Taxes																									Income Taxes
																									We account for income taxes using the liability method. Deferred tax assets or liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities as measured by the enacted tax rates which will be in effect when the differences reverse. A valuation allowance against net deferred tax assets is provided unless we conclude it is more likely than not that the deferred tax assets will be realized.
																									We recognize tax benefits from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by taxing authorities.
Unaudited Interim Financial Information	Unaudited Interim Financial Information
	The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United Stated of America (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Act of 1934. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for annual financial statements. The unaudited consolidated financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments, consisting of only normal recurring accruals considered necessary to present fairly our financial position at September 30, 2014, results of operations for the three and nine months ended September 30, 2014 and 2013, and cash flows for the nine months ended September 30, 2014 and 2013. The results of operations for the three and nine months ended September 30, 2014 are not necessarily indicative of the results that may be expected for the year ending December 31, 2014.
	The consolidated interim financial statements, including our significant accounting policies, should be read in conjunction with the audited Consolidated Financial Statements and the notes thereto for the year ended December 31, 2013, included in the Company’s Annual Report on Form 10-K as filed with the Securities and Exchange Commission on April 10, 2014 and amended on April 15, 2014.
Reclassifications	Reclassifications
Reclassifications	Certain prior year amounts have been reclassified to conform to the current year presentation.
Accounting Renouncements	Accounting Renouncements
Accounting Renouncements	The FASB issued ASU 2014-09 “Revenue from Contracts with Customers” clarifying the method used to determine the timing and requirements for revenue recognition on the statements of income. Under the new standard, an entity must identify the performance obligations in a contract, the transaction price and allocate the price to specific performance obligations to recognize the revenue when the obligation is completed. The amendments in this update also require disclosure of sufficient information to allow users to understand the nature, amount, timing and uncertainty of revenue and cash flow arising from contracts. The new accounting guidance is effective for interim and annual periods beginning after December 15, 2016. Luna is analyzing the impact of this new standard and, at this time, cannot estimate the impact of adoption on revenue or net income. Luna plans to adopt ASU 2014-09 effective January 1, 2017.

Organization_and_Summary_of_Si2

Organization and Summary of Significant Accounting Policies (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2014

Dec. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Property and Equipment Estimated Useful Lives

Property and equipment are stated at cost less accumulated depreciation. We record depreciation using the straight-line method over the following estimated useful lives:

Equipment

3 – 7 years

Furniture and fixtures

7 years

Software

3 years

Leasehold improvements

Lesser of lease term or life of improvements

Assumptions Used to Estimate Fair Value of Option Granted

The fair value of each option granted during the nine months ended September 30, 2014 and 2013 was estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:

The fair value of each option granted is estimated as of the grant date using the Black-Scholes option pricing model with the following assumptions:

Nine Months Ended

2012

2013

September 30, 2014

September 30, 2013

Risk-free interest rate range

1.02% – 1.49%

1.27% – 2.34%

Risk-free interest rate

2.14

1.27 - 2.34

Expected life of option-years

7.5

Expected life of options (in years)

7.5

Expected stock price volatility

108%

Expected stock price volatility

106

108

Executive turnover rates

— %

Non-executive turnover rates

18.50%

14.70%

Expected dividend yield

—

Inventory_Tables

Inventory (Tables)	9 Months Ended					12 Months Ended
Inventory (Tables)	Sep. 30, 2014					Dec. 31, 2013
Inventory Disclosure [Abstract]
Components of Inventory	Components of inventory are as follows:					Components of inventory are as follows:


		September 30,		December 31,			December 31,		December 31,
		2014		2013			2012		2013
	Finished goods	$	637,054	$	719,574	Finished goods	$	195,578	$	719,574
	Work-in-process		452,304		361,754	Work-in-process		252,227		361,754
	Parts		2,518,037		2,339,595	Parts		2,975,297		2,339,595

			3,607,395		3,420,923			3,423,102		3,420,923
	Less: Inventory reserves		207,263		74,746	Less: Inventory reserves		86,186		74,746

	Total inventory, net	$	3,400,132	$	3,346,177	Total inventory, net	$	3,336,916	$	3,346,177

Debt_Tables

Debt (Tables)	12 Months Ended
Debt (Tables)	Dec. 31, 2013
Debt Disclosure [Abstract]
Summary of Debt Outstanding	The following table presents a summary of debt outstanding as of December 31, 2012 and 2013:


		December 31,
		2012		2013
	Silicon Valley Bank Term Loan	$	3,625,000	$	2,125,000

	Less: current portion		1,500,000		1,500,000

	Total long-term debt	$	2,125,000	$	625,000

Maturities On Long-term Debt	Maturities on long-term debt are as follows:


	Year	Amount
	2014		1,500,000
	2015		625,000

	Total	$	2,125,000

Costs Associated with Loans Outstanding	Costs associated with loans outstanding were as follows:


		Years Ended December 31,
		2012		2013
	Interest expense	$	286,529	$	189,151
	Amortization of transaction costs		25,843		18,387

	Total interest expense	$	312,372	$	207,538

Accounts_ReceivableTrade_Table

Accounts Receivable-Trade (Tables)	12 Months Ended
Accounts Receivable-Trade (Tables)	Dec. 31, 2013
Receivables [Abstract]
Components of Accounts Receivable	Accounts receivable consist of the following:


		December 31,
		2012		2013
	Billed	$	5,175,395	$	3,552,184
	Unbilled		1,873,376		1,755,439
	Other		10,864		235,469

		$	7,059,635	$	5,543,092

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2013
Property, Plant and Equipment [Abstract]
Property Plant and Equipment Net	Property and equipment, net, consists of the following at:


		December 31,
		2012			2013
	Building	$	69,556		$	69,556
	Equipment		7,222,208			7,239,017
	Furniture and fixtures		622,944			562,485
	Software		1,185,290			1,092,484
	Leasehold improvements		3,196,590			3,168,377

			12,296,588			12,131,919
	Less—accumulated depreciation		(9,869,950	)		(10,071,210	)

		$	2,426,638		$	2,060,709

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Intangible Assets	The following is a summary of intangible assets:


		December 31,
		2012			2013
	Patent costs	$	2,264,441		$	2,496,560
	Accumulated amortization		(1,826,602	)		(2,208,085	)

		$	437,839		$	288,475

Estimated Aggregate Amortization Based On Net Value Of Intangible Assets	Estimated aggregate amortization, based on the net value of intangible assets at December 31, 2013, for each of the next five years is as follows:


	Year Ending December 31,
	2014		188,616
	2015		53,371
	2016		24,844
	2017		10,578
	2018		6,013

		$	283,422

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities consist of the following components:


		2012						2013
		Current			Long-Term			Current			Long-Term
	Bad debt and inventory reserve	$	41,243		$	—		$	88,077		$	—
	Deferred revenue		—			—			—			59,673
	Depreciation and amortization		—			1,005,697			—			1,024,784
	Net operating loss carryforwards		—			11,358,044			—			10,896,286
	Research and development credits		—			386,161			—			386,161
	Accrued liabilities		731,831			—			836,011			—
	Deferred compensation		—			123,797			—			163,655
	Stock-based compensation		—			1,208,970			—			1,519,513
	AMT credit		—			28,555			—			42,711

	Total		773,074			14,111,224			924,088			14,092,783
	Valuation allowance		(773,074	)		(14,111,224	)		(924,088	)		(14,092,783	)

	Net deferred tax asset	$	—		$	—		$	—		$	—

Reconciliation of Expected Income Tax Benefit (Expense) to Actual Income Tax Expense Benefit (Expense)	The reconciliation of expected income tax benefit (expense) to actual income tax expense benefit (expense) was as follows:


		2012			2013
	Statutory federal rate		34	%		34	%
	State tax net of federal benefit		3.73	%		3.96	%
	Change in valuation allowance		(4.16	)%		(16.88	)%
	Incentive stock options		(35.60	)%		(41.60	)%
	Provision to return adjustments		(1.80	)%		24.11	%
	Meals and entertainment		(0.74	)%		(1.33	)%
	Other Permanent differences		(0.60	)%		(4.37	)%

	Income tax (expense)		(5.17	)%		(2.11	)%

Components of Income Tax Expense	The income tax expense consists of the following for:


		2012			2013
	Current:
	Federal	$	18,268		$	14,071
	State		3,149			—
	Deferred Federal		—			—
	Deferred State		—			—

	Income tax expense	$	21,417		$	14,071

Capital_Stock_and_Additional_P1

Capital Stock and Additional Paid-in Capital (Tables)	9 Months Ended																			12 Months Ended
Capital Stock and Additional Paid-in Capital (Tables)	Sep. 30, 2014																			Dec. 31, 2013
Equity [Abstract]
Activity of Stock Options	A summary of the activity for our 2003 Stock Plan and 2006 Equity Incentive Plan is presented below for the nine months ended September 30, 2014:																			The following table sets forth the activity of the options to purchase common stock under the 2003 Plan and the 2006 Plan:


			Options Outstanding									Options Exercisable										Options Outstanding							Options Exercisable
			Number of			Price per		Weighted		Aggregate		Number of			Weighted			Aggregate				Number of			Price per		Weighted		Aggregate		Number		Weighted		Aggregate
			Shares			Share		Average		Intrinsic		Shares			Average			Intrinsic				Shares			Share		Average		Intrinsic		of		Average		Intrinsic
						Range		Exercise		Value (1)					Exercise			Value (1)							Range		Exercise		Value (1)		Shares		Exercise		Value (1)
								Price							Price												Price						Price
	Balance, January 1, 2014			5,279,229		$	0.35 - $6.55	$	2.11	$	784,154		4,012,378		$	2.28		$	697,826	Balance at January 1, 2012			4,641,039		$	0.35–6.74	$	2.23	$	1,509,270		3,206,994	$	2.23	$	1,258,740
	Granted			915,952		$	1.37 - $1.53	$	1.42											Forfeited			(64,245	)		0.65–5.50		1.91
	Exercised			(276,586	)	$	0.35 - $1.27	$	0.79											Exercised			(182,702	)		0.35–1.77		0.38
	Canceled			(1,470,336	)	$	0.35 - $6.55	$	1.4											Granted			1,028,038			1.40–1.75		1.67

	Balance, September 30, 2014			4,448,259		$	0.35 - $6.55	$	1.92	$	494,279		3,055,457		$	2.11		$	459,175	Balance at December 31, 2012			5,422,130		$	0.35–6.74	$	2.19	$	639,904		3,775,388	$	2.37	$	604,292
																				Forfeited			(693,644	)		0.35–6.74		2.08
																				Exercised			(137,097	)		0.35–1.18		0.56
	-1	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-the-money options only. The aggregate intrinsic value is based on the closing price of Luna’s common stock on the NASDAQ Capital Market, as applicable, on the respective dates.																		Granted			687,840			1.20–1.31		1.29

																				Balance at December 31, 2013			5,279,229		$	0.35–6.55	$	2.11	$	784,154		4,012,378	$	2.28	$	697,826


																				-1	The intrinsic value of an option represents the amount by which the market value of the stock exceeds the exercise price of the option of in-money options only. The prices represent the closing price of our Common Stock on the NASDAQ Capital Market on the respective dates.
Activity of Stock Option by Exercise Price Range
																									Options Outstanding						Options Exercisable
																						Range of			Options		Weighted		Weighted		Options		Weighted
																						Exercise Prices			Outstanding		Average		Average		Exercisable		Average
																											Remaining		Exercise				Exercise
																											Life in		Price				Price of
																											Years						Options
																																	Exercisable
																				Year ended December 31, 2012		$	0.35–6.74			5,422,130		6.39	$	2.19		3,775,388	$	2.37
																				Year ended December 31, 2013		$	0.35–6.55			5,279,229		5.88	$	2.11		4,012,378	$	2.28


																						Total intrinsic value of			Total fair value of
																						options exercised			options vested
																				Year ended December 31, 2012		$	215,541		$	1,170,738
																				Year ended December 31, 2013		$	111,595		$	1,248,067
Equity Transactions	The following details our equity transactions during the nine months ended September 30, 2014:


			Preferred Stock					Common Stock				Treasury Stock						Additional
																		Paid-in
																		Capital
			Shares			$		Shares		$		Shares			$			$
	Balances, December 31, 2013			1,321,514			1,322		14,527,335		14,842		—			—			62,756,571
	Exercise of stock options			—			—		276,586		277		—			—			217,668
	Share-based compensation			—			—		268,500		209		—			—			766,724
	Stock dividends to Carilion Clinic (1)			—			—		—		59		—			—			83,572
	Purchase of treasury stock												(22,725	)		(32,221	)

	Balances, September 30, 2014			1,321,514			1,322		15,072,421		15,387		(22,725	)		(32,221	)		63,824,535


	-1	The stock dividends payable in connection with Carilion Clinic’s Series A Preferred Stock will be issued subsequent to September 30, 2014. For the period from January 12, 2010, the original issue date of the Series A Preferred Stock, through September 30, 2014, the Series A Preferred Stock issued to Carilion has accrued $793,807 in dividends. The accrued and unpaid dividends as of September 30, 2014 will be paid by the issuance of 373,994 shares of our common stock upon Carilion’s written request.

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Future Minimum Rental Payments for Operating Leases	Minimum future rentals, as of December 31, 2013, under the aforementioned operating leases for each of the next five years are:


	2014		1,014,131
	2015		503,760
	2016		299,635
	2017		305,628
	2018		311,740

		$	2,434,894

Financial_Information_About_Se1

Financial Information About Segments (Tables)	9 Months Ended													12 Months Ended
Financial Information About Segments (Tables)	Sep. 30, 2014													Dec. 31, 2013
Segment Reporting [Abstract]
Information About Results of Operations for Each Segment														Information about the results of operations for each segment is set forth in the table below. There were no significant inter-segment sales during the two years ended December 31, 2013. There was an insignificant amount of product sales made outside the United States during these two years.



															Year Ended December 31,
															2012			2013
														Technology Development revenue	$	15,126,834		$	11,421,868
														Products and Licensing revenue		8,338,967			6,911,707

														Total revenue		23,465,801			18,333,575

														Technology Development operating loss		(1,703,370	)		(3,169,605	)
														Products and Licensing operating loss		(2,426,707	)		(4,865,705	)

														Total operating loss from continuing operations		(4,130,077	)	$	(8,035,310	)

														Depreciation, Technology Development	$	499,439		$	286,894
														Depreciation, Products and Licensing		266,327			266,862
														Amortization, Technology Development		212,790			197,765
														Amortization, Products and Licensing		113,471			183,956
Segment Information														Additional segment information is as follows:


															December 31,
															2012			2013
														Total segment assets:
														Technology Development	$	13,342,725		$	10,208,433
														Products and Licensing		7,115,043			9,495,642

														Total	$	20,457,768		$	19,704,075

														Property plant and equipment and intangible assets, Technology Development	$	1,868,235		$	1,217,083
														Property plant and equipment and intangible assets, Products and Licensing	$	996,242		$	1,132,101

Schedule of revenues, operating loss and assets for reportable segments	The table below presents revenues and operating loss for reportable segments not including discontinued operations:


		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
		(unaudited)						(unaudited)
	Revenues:
	Technology development revenues	$	3,067,022		$	3,130,206		$	8,961,909		$	8,564,743
	Products and licensing revenues		2,303,508			1,568,646			6,108,799			5,070,441

	Total revenues	$	5,370,530		$	4,698,852		$	15,070,708		$	13,635,184

	Technology development operating loss	$	(299,980	)	$	(259,486	)	$	(2,835,120	)	$	(599,303	)
	Products and licensing operating loss		(420,010	)		(1,042,526	)		(800,240	)		(4,683,929	)

	Total operating loss	$	(719,990	)	$	(1,302,012	)	$	(3,635,360	)	$	(5,283,232	)

	Depreciation, technology development	$	49,592		$	86,413		$	160,327		$	272,570
	Depreciation, products and licensing	$	37,247		$	43,304		$	109,037		$	161,426
	Amortization, technology development	$	38,641		$	61,563		$	131,615		$	173,140
	Amortization, products and licensing	$	29,022		$	30,851		$	90,087		$	104,239
	The table below presents assets for reportable segments:


		September 30,			December 31,
		2014			2013
	Total segment assets:
	Technology development	$	14,902,005		$	10,208,433
	Products and licensing		11,192,253			9,495,642

	Total	$	26,094,258		$	19,704,075

	Property plant and equipment, and intangible assets, technology development	$	1,198,066		$	1,217,083
	Property plant and equipment, and intangible assets, products and licensing	$	899,816		$	1,132,101

Quarterly_Results_unaudited_Ta

Quarterly Results (unaudited) (Tables)	12 Months Ended
Quarterly Results (unaudited) (Tables)	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Schedule of Quarterly Financial Information	The following table sets forth our unaudited historical revenues, operating loss and net (loss) income by quarter during 2012 and 2013.



		Quarter Ended
	(Dollars in thousands,	March 31,			June 30,			September 30,			December 31,			March 31,			June 30,			September 30,			December 31,
		2012			2012			2012			2012			2013			2013			2013			2013
	except per share amounts)
	Revenues:
	Technology	$	3,943		$	3,895		$	3,691		$	3,598		$	2,627		$	2,807		$	3,130		$	2,858
	Products and licensing		2,338			1.993			2,021			1,986			1,478			2,024			1,569			1,841

	Total revenues		6,281			5,888			5,712			5,584			4,105			4,831			4,699			4,699
	Gross Margin		2,533			2,315			2,266			1,778			1,135			1,777			1,677			1,460
	Operating loss		(867	)		(922	)		(1,020	)		(1,322	)		(2,241	)		(1,739	)		(1,302	)		(2,753	)
	Loss from continuing operations, net		(712	)		(681	)		(759	)		(1,076	)		(1,319	)		(1,035	)		(775	)		(2,379	)
	Income/(loss) from discontinued operations net of income taxes		378			438			539			489			4,105			83			161			356
	Net income/(loss)		(334	)		(243	)		(220	)		(587	)		2,786			(952	)		(614	)		(2,023	)
	Net (loss)/income attributable to common stockholders	$	(369	)	$	(269	)	$	(254	)	$	(612	)	$	2,762		$	(978	)	$	(640	)	$	(2,049	)

	Net loss per share from continuing operations:
	Basic	$	(0.05	)	$	(0.05	)	$	(0.05	)	$	(0.08	)	$	(0.09	)	$	(0.07	)	$	(0.05	)	$	(0.16	)
	Diluted	$	(0.05	)	$	(0.05	)	$	(0.05	)	$	(0.08	)	$	(0.09	)	$	(0.07	)	$	(0.05	)	$	(0.16	)
	Net income/(loss) per share from discontinued operations:
	Basic	$	0.03		$	0.03		$	0.04		$	0.03		$	0.29		$	0.01		$	0.01		$	0.03
	Diluted	$	0.03		$	0.03		$	0.04		$	0.03		$	0.29		$	0.01		$	0.01		$	0.03
	Net (loss)/income attributable to common stockholders:
	Basic	$	(0.03	)	$	(0.02	)	$	(0.02	)	$	(0.04	)	$	0.2		$	(0.07	)	$	(0.04	)	$	(0.14	)
	Diluted	$	(0.03	)	$	(0.02	)	$	(0.02	)	$	(0.04	)	$	0.2		$	(0.07	)	$	(0.04	)	$	(0.14	)
	Weighted average shares:
	Basic and Diluted		13,850,667			13,892,816			13,939,938			14,008,772			14,011,814			14,362,494			14,441,707			14,488,060

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended												12 Months Ended
Discontinued Operations (Tables)	Sep. 30, 2014												Dec. 31, 2013
Discontinued Operations and Disposal Groups [Abstract]
Components of (Loss) Income from Discontinued Operations	The key components of income from discontinued operations were as follows:												The key components of income/ (loss) from discontinued operations were as follows:


		Three Months Ended						Nine Months Ended						Year Ended December 31,
		September 30, 2014			September 30, 2013			September 30, 2014			September 30, 2013			2012		2013
	Net revenues	$	—		$	1,578,308		$	—		$	4,343,391	Net revenues	$	8,883,202	$	5,909,375
	Cost of revenues		—			927,847			46,204			2,623,286	Cost of revenues		5,337,336		3,486,200
	Operating expenses		—			—			—			229,745	Operating expenses		574,446		229,745

	Income/(loss) before income taxes		—			650,461			(46,204	)		1,490,360	Income/(loss) before income taxes		2,971,420		2,193,430
	Allocated tax expense/(benefit)		52			255,905			(18,077	)		590,181	Allocated tax expense/(benefit)		1,127,981		879,819

	Operating (loss)/income from discontinued operations, net of income taxes		(52	)		394,556			(28,127	)		900,179	Operating income/(loss) from discontinued operations		1,843,439		1,313,611
	(Loss)/gain on sale, net of $0.3 million, $0.2 million, $1.6 million and $1.5 million of related income taxes		(277,562	)		(233,889	)		9,093,268			3,448,270	Gain on sale, net of $1.5 million of related income taxes		—		3,391,639

	(Loss)/income from discontinued operations, net of income taxes	$	(277,614	)	$	160,667		$	9,065,141		$	4,348,449	Income from discontinued operations, net of income taxes ($1.0 million and $2.4 million, respectively)	$	1,843,439	$	4,705,250

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]
Schedule of Earnings Per Share	Earnings Per Share



		Net loss per share from continuing												Net (loss)/income attributable to common
		operations												stockholders
		For the three months						For the nine months						For the three months						For the nine months
		ended September 30,						ended September 30,						ended September 30,						ended September 30,
		2014			2013			2014			2013			2014			2013			2014		2013
	Numerator:
	Net loss from continuing operations	$	(466,556	)	$	(774,579	)	$	(2,184,989	)	$	(3,128,846	)
	Net (loss)/income attributable to stockholders													$	(770,930	)	$	(640,078	)	$	6,796,522	$	1,143,442
	Denominator:
	Basic weighted average common shares outstanding		15,016,429			14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			14,821,619		14,285,829
	Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards		—			—			—			—			—			—			—		—
	Convertible preferred stock		—			—			—			—			—			—			—		—
	Preferred stock dividends		—			—			—			—			—			—			—		—

	Diluted weighted average common shares outstanding		15,016,429			14,441,707			14,821,619			14,285,829			15,016,429			14,441,707			17,185,369		16,593,102
	Basic net loss per share from continuing operations	$	(0.03	)	$	(0.05	)	$	(0.15	)	$	(0.22	)
	Diluted net loss per share from continuing operations	$	(0.03	)	$	(0.05	)	$	(0.15	)	$	(0.22	)
	Basic net (loss)/income per share attributable to common stockholders													$	(0.05	)	$	(0.04	)	$	0.46	$	0.08
	Diluted net (loss)/income per share attributable to common stockholders													$	(0.05	)	$	(0.04	)	$	0.46	$	0.08

	Weighted-average anti-dilutive shares related to:
	Outstanding stock options		4,448,259			5,322,656			4,086,208			5,322,686			4,448,259			5,322,656			3,005,297		4,095,725
	Convertible preferred stock		1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			1,321,514			1,321,514		1,321,514
	Preferred stock dividends		373,994			274,879			354,171			255,056			373,994			274,879			354,171		255,056
	Restricted stock		330,160			261,257			290,394			219,759			330,160			261,257			290,394		219,759
	Carilion warrants		366,000			366,000			366,000			366,000			366,000			366,000			366,000		366,000

Accrued_Liabilities_Tables

Accrued Liabilities (Tables)	9 Months Ended
Accrued Liabilities (Tables)	Sep. 30, 2014
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities
		September 30, 2014		December 31, 2013
	Accrued compensation	$	2,111,858	$	2,205,612
	Accrued sub-contracts		309,570		297,510
	Accrued professional fees		20,885		279,991
	Accrued income tax		162,105		13,143
	Deferred rent		72,477		102,569
	Royalties		344,383		291,442
	Warranty reserve		61,850		56,700
	Claims reserve		—		92,167
	Accrued liabilities—other		375,328		207,451

	Total Accrued Liabilities	$	3,458,456	$	3,546,585

Organization_and_Summary_of_Si3

Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended		1 Months Ended	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2010	Dec. 31, 2011	Jan. 21, 2014	Mar. 01, 2013
	Sep. 30, 2014	Sep. 30, 2013	Segment	Sep. 30, 2013	Segment	Dec. 31, 2012	Jan. 31, 2010	Dec. 31, 2011	Jan. 21, 2014	Mar. 01, 2013
Significant Accounting Policies [Line Items]
Number of operating segments			2		2
Sale price of assets to an unaffiliated third party									$30,000,000	$6,100,000
Dividend on preferred stock, shares of common stock issuable			0	0
Allowance for uncollectible receivables					134,811	0
Cash Equivalents					7,500,000	6,100,000
Research, development, and engineering	473,527	531,185	1,707,190	1,932,966	3,113,193	2,772,438
Patents
Significant Accounting Policies [Line Items]
Finite lived intangible asset, useful life					5 years
Stock Option and Warrant
Significant Accounting Policies [Line Items]
Antidilutive securities excluded from computation of earnings per share amount					2,300,000	2,400,000
Carilion Clinic
Significant Accounting Policies [Line Items]
Senior convertible Promissory Notes principal amount converted							5,000,000
Accrued interest converted							1,200,000
Warrants issued in exchange of notes payable, shares							356,000
Warrant exercise price (in dollars per share)							2.5
Percentage of Dividend Payable On Series A Convertible Preferred Stock							6.00%
Dividend on preferred stock, shares of common stock issuable					314,525
Conversion of stock description					Each share of Series A Convertible Preferred Stock may be converted into one share of our common stock at the option of the holder.
Maximum \| Carilion Clinic
Significant Accounting Policies [Line Items]
Preferred stock liquidation preference value							$6,200,000
Before Amendment \| Carilion Clinic
Significant Accounting Policies [Line Items]
Warrant exercise price (in dollars per share)							7.98
Before Amendment \| Maximum \| Carilion Clinic
Significant Accounting Policies [Line Items]
Warrant exercisable date								31-Dec-20
After Amendment \| Carilion Clinic
Significant Accounting Policies [Line Items]
Warrant exercise price (in dollars per share)							2.5
Warrant exercisable date							31-Dec-20
Series A Preferred Stock \| Carilion Clinic
Significant Accounting Policies [Line Items]
Preferred stock issued in exchange of notes payable, shares							1,321,514

Organization_and_Summary_of_Si4

Organization and Summary of Significant Accounting Policies - Property and Equipment Estimated Useful Lives (Detail)	12 Months Ended
	Dec. 31, 2013
Equipment \| Minimum
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Equipment \| Maximum
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	7 years
Furniture and Fixtures
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	7 years
Software
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	3 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Property plant and equipment useful life	Lesser of lease term or life of improvements

Organization_and_Summary_of_Si5

Organization and Summary of Significant Accounting Policies - Assumptions Used to Estimate Fair Values of Option Granted (Detail)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Risk-free interest rate	2.14%		1.27%	1.02%
Risk-free interest rate, maximum			2.34%	1.49%
Expected life of option-years	7 years 6 months	7 years 6 months	7 years 6 months	7 years 6 months
Expected stock price volatility	106.00%	108.00%	108.00%	108.00%
Executive turnover rates			0.00%	0.00%
Non-executive turnover rates			14.70%	18.50%
Expected dividend yield	0.00%		0.00%	0.00%

Inventory_Components_of_Invent

Inventory - Components of Inventory (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Finished goods	$637,054	$719,574	$195,578
Work-in-process	452,304	361,754	252,227
Parts	2,518,037	2,339,595	2,975,297
Total inventory, gross	3,607,395	3,420,923	3,423,102
Less: Inventory reserves	207,263	74,746	86,186
Total inventory, net	$3,400,132	$3,346,177	$3,336,916

Debt_Additional_Information_De

Debt - Additional Information (Detail) (USD $)	0 Months Ended	9 Months Ended	12 Months Ended
	Oct. 15, 2014	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 21, 2014	Mar. 21, 2013
	Oct. 15, 2014	Installment	Installment	Dec. 31, 2012	Jan. 21, 2014	Mar. 21, 2013
Debt Instrument [Line Items]
Long-term debt obligation			$2,125,000
Long-term debt obligation, excluding current maturities		0	625,000	2,125,000
Current portion of long term debt obligation		1,000,000	1,500,000	1,500,000
Line of Credit, outstanding amount			0
Credit facility, available borrowing capacity			1,000,000
Subsequent Event \| Letter of Credit
Debt Instrument [Line Items]
Line of Credit Facility, Borrowing Requested in Connection with Lease Financing	500,000
Term Loan
Debt Instrument [Line Items]
Debt, face amount		6,000,000
Debt, number of monthly payment		48
Debt instrument frequency of payment		Monthly
Debt, additional interest above prime rate		2.00%
Debt Instrument, Interest Rate During Period		6.00%
Term Loan \| Silicon Valley Bank
Debt Instrument [Line Items]
Current portion of long term debt obligation		1,000,000
Revolving Credit Facility \| Second and Third Amendment \| Silicon Valley Bank Term Loan
Debt Instrument [Line Items]
Debt, additional interest above prime rate		1.25%
Credit facility, maximum borrowing capacity		1,000,000
Credit facility, maturity date		17-May-14
Revolving Credit Facility \| Second and Third Amendment \| Silicon Valley Bank Term Loan \| Monthly Payment
Debt Instrument [Line Items]
Unused Line of Credit fee percentage		0.25%
Frequency of commitment fee payment		Monthly
Revolving Credit Facility \| Fourth Loan Modification Agreement
Debt Instrument [Line Items]
Maintaining minimum cash balance as per covenant					3,000,000	5,000,000
Term Loan
Debt Instrument [Line Items]
Debt, face amount			6,000,000
Debt, number of monthly payment			48
Debt instrument frequency of payment			Monthly
Debt, additional interest above prime rate			2.00%
Long-term debt obligation			2,100,000
Long-term debt obligation, excluding current maturities			600,000
Current portion of long term debt obligation			1,500,000
Effective interest rate			6.00%
Term Loan \| Silicon Valley Bank Term Loan
Debt Instrument [Line Items]
Long-term debt obligation			2,125,000	3,625,000
Revolving Credit Facility \| Fourth Loan Modification Agreement
Debt Instrument [Line Items]
Maintaining minimum cash balance as per covenant						5,000,000
Revolving Credit Facility \| Fourth Loan Modification Agreement \| Subsequent Event
Debt Instrument [Line Items]
Maintaining minimum cash balance as per covenant					3,500,000
Revolving Credit Facility \| Silicon Valley Bank Term Loan \| Second and Third Amendment
Debt Instrument [Line Items]
Debt, additional interest above prime rate			1.25%
Credit facility, maximum borrowing capacity			1,000,000
Unused Line of Credit fee percentage			0.25%
Termination fee			$10,000
Credit facility, maturity date			18-May-14

Debt_Summary_of_Debt_Outstandi

Debt - Summary of Debt Outstanding (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]
Long term debt		$2,125,000
Less: current portion	1,000,000	1,500,000	1,500,000
Total long-term debt	0	625,000	2,125,000
Term Loan
Debt Instrument [Line Items]
Long term debt		2,100,000
Less: current portion		1,500,000
Total long-term debt		600,000
Silicon Valley Bank Term Loan \| Term Loan
Debt Instrument [Line Items]
Long term debt		$2,125,000	$3,625,000

Debt_Maturities_on_Long_Term_D

Debt - Maturities on Long Term Debt (Detail) (USD $)	Dec. 31, 2013
Debt Disclosure [Abstract]
2014	$1,500,000
2015	625,000
Total	$2,125,000

Debt_Costs_Associated_With_Loa

Debt - Costs Associated With Loans Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Debt Disclosure [Abstract]
Interest expense	$189,151	$286,529
Amortization of transaction costs	18,387	25,843
Total interest expense	$207,538	$312,372

Accounts_ReceivableTrade_Compo

Accounts Receivable-Trade - Components of Accounts Receivable (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Receivables [Abstract]
Billed	$3,552,184	$5,175,395
Unbilled	1,755,439	1,873,376
Other	235,469	10,864
Accounts Receivable, Gross, Total	5,543,092	7,059,635
Less: allowance for doubtful accounts	-134,811	0
Accounts Receivable, Net, Total	$5,408,281	$7,059,635

Property_and_Equipment_Compone

Property and Equipment - Components of Property and Equipment, Net (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Building		$69,556	$69,556
Equipment		7,239,017	7,222,208
Furniture and fixtures		562,485	622,944
Software		1,092,484	1,185,290
Leasehold improvements		3,168,377	3,196,590
Property, Plant and Equipment, Gross, Total		12,131,919	12,296,588
Less-accumulated depreciation		-10,071,210	-9,869,950
Property and equipment, net	$1,917,164	$2,060,709	$2,426,638

Property_and_Equipment_Additio

Property and Equipment - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Property, Plant and Equipment [Abstract]
Depreciation	$0.50	$0.80

Intangible_Assets_Summary_of_I

Intangible Assets - Summary of Intangible Assets (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization		($2,208,085)	($1,826,602)
Intangible assets, net	180,718	288,475	437,839
Patents
Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets gross		$2,496,560	$2,264,441

Intangible_Assets_Additional_I

Intangible Assets - Additional Information (Detail) (USD $)	12 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$0.40	$0.30

Intangible_Assets_Estimated_Ag

Intangible Assets - Estimated Aggregate Amortization (Detail) (USD $)	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
2014	$188,616
2015	53,371
2016	24,844
2017	10,578
2018	6,013
Finite-Lived Intangible Assets, Net, Total	$283,422

Income_Taxes_Deferred_Tax_Asse

Income Taxes - Deferred Tax Assets and Liabilities (Detail) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Deferred Income Tax Assets And Liabilities [Line Items]
Total, current	$924,088	$773,074
Valuation allowance, current	-924,088	-773,074
Net deferred tax asset, current	0	0
Total	14,092,783	14,111,224
Valuation allowance	-14,092,783	-14,111,224
Net deferred tax asset	0	0
Deferred Tax Assets Noncurrent
Deferred Income Tax Assets And Liabilities [Line Items]
Deferred revenue	59,673
Depreciation and amortization	1,024,784	1,005,697
Net operating loss carryforwards	10,896,286	11,358,044
Research and development credits	386,161	386,161
Deferred compensation	163,655	123,797
Stock-based compensation	1,519,513	1,208,970
AMT credit	42,711	28,555
Deferred Tax Assets Current
Deferred Income Tax Assets And Liabilities [Line Items]
Bad debt and inventory reserve	88,077	41,243
Accrued liabilities	$836,011	$731,831

Income_Taxes_Reconciliation_of

Income Taxes - Reconciliation of Expected Income Tax Benefit (Expense) to Actual Income Tax Expense Benefit (Expense) (Detail)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Statutory federal rate	34.00%	34.00%
State tax net of federal benefit	3.96%	3.73%
Change in valuation allowance	-16.88%	-4.16%
Incentive stock options	-41.60%	-35.60%
Provision to return adjustments	24.11%	-1.80%
Meals and entertainment	-1.33%	-0.74%
Other Permanent differences	-4.37%	-0.60%
Income tax (expense)	-2.11%	-5.17%

Income_Taxes_Components_of_Inc

Income Taxes - Components of Income Tax Expense (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Current:
Federal	$14,071	$18,268
State		3,149
Deferred Federal	0	0
Deferred State	0	0
Income tax expense	$14,071	$21,417

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2013
Income Taxes [Line Items]
Net Operating Loss Carry forwards	$28,700,000
Expiration Dates	2025
Research and Development Tax Credit	400,000
Research & development tax credit carryforwards expiration date	2024
U.S. Federal Statute Of Limitations Remains Open For Year	2005 and onward
Income Tax Examination Description	We currently have no federal income tax returns under examination. U.S. state jurisdictions have statutes of limitation generally ranging from three to seven years. We currently have no state income or franchise tax returns under examination. We currently do not file tax returns in any foreign tax jurisdiction.
Unrecognized Tax Benefits Net Increases Decreases Resulting From Current Period Tax Positions	0
Windfall Stock Compensation Deductions	$165,000
Minimum
Income Taxes [Line Items]
Income Tax Examination Statute Of Limitations Period	3 years
Maximum
Income Taxes [Line Items]
Income Tax Examination Statute Of Limitations Period	7 years

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)	9 Months Ended	12 Months Ended		1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Jan. 31, 2006	Apr. 30, 2003	Jan. 31, 2010	Dec. 31, 2011	Feb. 04, 2006
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Options outstanding (in shares)	4,448,259	5,279,229	5,422,130				4,641,039
Employee Vesting Period		5 years
Stock option expense		$1,200,000	$1,900,000
Weighted average grant date fair value of options granted (in dollars per share)		$1.29	$1.10
Stock-based compensation expense expected to recognize	1,600,000	1,600,000
Weighted average remaining service	1 year 7 months 6 days	1 year 8 months 12 days
2003 Stock Option Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Stock option contractual term				10 years	10 years
Number of shares reserved for future issuance								9,715,000
Options outstanding (in shares)		945,472
2006 Equity Incentive Plan
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Number of shares available for issuance increases, percentage of outstanding common stock				10.00%
Potential number of shares available for issuance increases				1,695,690
Shares available for future grant		10,468,175	8,872,540
Description of shares available for issuance				The number of shares available for issuance increases by the lesser of (a) 10% of the outstanding shares of our common stock on the last day of the preceding fiscal year; (b) 1,695,690 shares; or (c) such other amount as our Board of Directors may determine.
Carilion Clinic
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Senior convertible Promissory Notes principal amount converted						5,000,000
Accrued interest converted						1,200,000
Percentage of Dividend Payable On Series A Convertible Preferred Stock						6.00%
Shares of common stock dividends		314,525
Conversion of stock description		Each share of Series A Convertible Preferred Stock may be converted into one share of our common stock at the option of the holder.
Conversion of stock, ratio			1
Warrant exercise price (in dollars per share)						2.5
Carilion Clinic \| Maximum
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Preferred stock liquidation preference value						6,200,000
Carilion Clinic \| Series A Preferred Stock
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Preferred stock issued in exchange of notes payable, shares						1,321,514
Hansen
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Issuance of Common Stock, Hansen Settlement (In shares)						1,247,330
Warrant exercise price (in dollars per share)						0.01
Common Stock Shares Outstanding Ownership Percentage						9.90%
Common stock issued upon exercise of warrant (in shares)		32,180	0
Warrant expense recognized		$0	$17,190

Stockholders_Equity_Activity_o

Stockholders' Equity - Activity of Stock Options (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Options Outstanding, Number of Shares
Beginning Balance (in shares)	5,279,229	5,422,130	4,641,039
Forfeited (in shares)		-693,644	-64,245
Exercised (in shares)	-276,586	-137,097	-182,702
Granted (in shares)	915,952	687,840	1,028,038
Ending Balance (in shares)	4,448,259	5,279,229	5,422,130
Options Outstanding, Price per Share Range
Beginning Balance, lower limit (in dollars per share)	$0.35	$0.35	$0.35
Beginning Balance, upper limit (in dollars per share)	$6.55	$6.74	$6.74
Forfeited, lower limit (in dollars per share)		$0.35	$0.65
Forfeited, upper limit (in dollars per share)		$6.74	$5.50
Exercised, lower limit (in dollars per share)	$0.35	$0.35	$0.35
Exercised, upper limit (in dollars per share)	$1.27	$1.18	$1.77
Granted, lower limit (in dollars per share)	$1.37	$1.20	$1.40
Granted, upper limit (in dollars per share)	$1.53	$1.31	$1.75
Ending Balance, lower limit (in dollars per share)		$0.35	$0.35
Balance Balance, upper limit (in dollars per share)	$6.55	$6.55	$6.74
Options Outstanding, Weighted Average Exercise Price
Beginning Balance (in dollars per share)	$2.11	$2.19	$2.23
Forfeited (in dollars per share)		$2.08	$1.91
Exercised (in dollars per share)	$0.79	$0.56	$0.38
Granted (in dollars per share)	$1.42	$1.29	$1.67
Ending balance (in dollars per share)	$1.92	$2.11	$2.19
Options Outstanding, Aggregate Intrinsic Value ending balance	$494,279	$784,154	$639,904	$1,509,270
Options Exercisable, Ending Balance (in shares)	3,055,457	4,012,378	3,775,388	3,206,994
Options Exercisable, Weighted Average Exercise Price ending balance (in dollars per share)	$2.11	$2.28	$2.37	$2.23
Options Exercisable, Aggregate Intrinsic Value ending balance	$459,175	$697,826	$604,292	$1,258,740

Stockholders_Equity_Activity_o1

Stockholders' Equity - Activity of Stock Option by Exercise Price Range (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014	Dec. 31, 2011
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, End of Period [Abstract]
Range of Exercise Prices, lower range (in dollars per share)	$0.35	$0.35
Range of Exercise Prices, upper range (in dollars per share)	$6.55	$6.74
Options outstanding (in shares)	5,279,229	5,422,130	4,448,259	4,641,039
Options Outstanding, Weighted Average Remaining Life in Years	5 years 10 months 17 days	6 years 4 months 21 days
Options Outstanding, Weighted Average Exercise Price (in dollars per share)	$2.11	$2.19	$1.92	$2.23
Options Exercisable (in shares)	4,012,378	3,775,388	3,055,457	3,206,994
Weighted Average Exercise Price of Options Exercisable (in dollars per share)	$2.28	$2.37	$2.11	$2.23
Total intrinsic value of options exercised	$111,595	$215,541
Total fair value of options vested	$1,248,067	$1,170,738

Commitment_and_Contingencies_A

Commitment and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2012	Sep. 30, 2014
Commitments and Contingencies Disclosure [Line Items]
Sublease income		$266,000
Operating leases, expiration period		2 years
Non-cancelable purchase order commitment	1,400,000	1,400,000
Non-cancelable purchase order delivery period	18 months
Non-cancelable purchase order commitment remained	1,400,000	1,400,000		700,000
Minimum Royalty Payable	1,800,000	1,800,000
Selling, General and Administrative Expenses
Commitments and Contingencies Disclosure [Line Items]
Lease and rental expense		$1,000,000	$1,300,000

Commitment_and_Contingencies_F

Commitment and Contingencies - Future Minimum Rental Payments for Operating Leases (Detail) (USD $)	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
2014	$1,014,131
2015	503,760
2016	299,635
2017	305,628
2018	311,740
Operating Leases, Future Minimum Payments Due, Total	$2,434,894

Employee_Profit_Sharing_Plan_A

Employee Profit Sharing Plan - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Defined Contribution Plan Service Period For Eligibility	3 months
Percentage of employer's matching contributions to a defined contribution plan that vests	25.00%
Percentage of employees' gross pay for which employer contributes a matching contribution	10.00%
Contribution To Employee Compensation Plan by Employer	$175,000	$250,000

Recovered_Sheet1

Relationship With Major Customers - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Sales
Segment Reporting Disclosure [Line Items]
SCC group accounted percentage of revenue to total revenue					12.00%
United States Government \| Sales
Segment Reporting Disclosure [Line Items]
SCC group accounted percentage of revenue to total revenue	60.00%	62.00%	60.00%	56.00%	64.00%	66.00%
United States Government \| Accounts Receivable
Segment Reporting Disclosure [Line Items]
Percentage of Trade Receivables					25.00%	34.00%

Financial_Information_About_Se2

Financial Information About Segments - Additional Information (Detail)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
	Segment	Segment
Segment Reporting [Abstract]
Number of operating segments	2	2

Financial_Information_About_Se3

Financial Information About Segments - Information About Results of Operations for Each Segment (Detail) (USD $)	3 Months Ended									9 Months Ended		12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Technology Development revenue	$3,067,022	$2,858,000	$3,130,206	$2,807,000	$2,627,000	$3,598,000	$3,691,000	$3,895,000	$3,943,000	$8,961,909	$8,564,743	$11,421,868	$15,126,834
Products and Licensing revenue	2,303,508	1,841,000	1,568,646	2,024,000	1,478,000	1,986,000	2,021,000	1,993,000	2,338,000	6,108,799	5,070,441	6,911,707	8,338,967
Total revenue	5,370,530	4,699,000	4,698,852	4,831,000	4,105,000	5,584,000	5,712,000	5,888,000	6,281,000	15,070,708	13,635,184	18,333,575	23,465,801
Operating income (loss)	-719,990	-2,753,000	-1,302,012	-1,739,000	-2,241,000	-1,322,000	-1,020,000	-922,000	-867,000	-3,635,360	-5,283,232	-8,035,310	-4,130,077
Depreciation												500,000	800,000
Amortization												400,000	300,000
Technology Development
Segment Reporting Information [Line Items]
Operating income (loss)	-299,980		-259,486							-2,835,120	-599,303	-3,169,605	-1,703,370
Depreciation	49,592		86,413							160,327	272,570	286,894	499,439
Amortization	38,641		61,563							131,615	173,140	197,765	212,790
Products and Licensing
Segment Reporting Information [Line Items]
Operating income (loss)	-420,010		-1,042,526							-800,240	-4,683,929	-4,865,705	-2,426,707
Depreciation	37,247		43,304							109,037	161,426	266,862	266,327
Amortization	$29,022		$30,851							$90,087	$104,239	$183,956	$113,471

Financial_Information_About_Se4

Financial Information About Segments - Segment Information (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$26,094,258	$19,704,075	$20,457,768
Property plant and equipment, and intangible assets	1,917,164	2,060,709	2,426,638
Technology Development
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	14,902,005	10,208,433	13,342,725
Property plant and equipment, and intangible assets	1,198,066	1,217,083	1,868,235
Products and Licensing
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	11,192,253	9,495,642	7,115,043
Property plant and equipment, and intangible assets	$899,816	$1,132,101	$996,242

Quarterly_Results_unaudited_Sc

Quarterly Results (unaudited) - Schedule of Quarterly Financial Information (Detail) (USD $)	3 Months Ended									9 Months Ended		12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Technology	$3,067,022	$2,858,000	$3,130,206	$2,807,000	$2,627,000	$3,598,000	$3,691,000	$3,895,000	$3,943,000	$8,961,909	$8,564,743	$11,421,868	$15,126,834
Products and licensing revenues	2,303,508	1,841,000	1,568,646	2,024,000	1,478,000	1,986,000	2,021,000	1,993,000	2,338,000	6,108,799	5,070,441	6,911,707	8,338,967
Total revenues	5,370,530	4,699,000	4,698,852	4,831,000	4,105,000	5,584,000	5,712,000	5,888,000	6,281,000	15,070,708	13,635,184	18,333,575	23,465,801
Gross Margin	2,083,250	1,460,000	1,677,145	1,777,000	1,135,000	1,778,000	2,266,000	2,315,000	2,533,000	5,623,342	4,636,275	6,048,658	8,891,805
Operating loss	-719,990	-2,753,000	-1,302,012	-1,739,000	-2,241,000	-1,322,000	-1,020,000	-922,000	-867,000	-3,635,360	-5,283,232	-8,035,310	-4,130,077
Net loss from continuing operations	-466,556	-2,379,000	-774,579	-1,035,000	-1,319,000	-1,076,000	-759,000	-681,000	-712,000	-2,184,989	-3,128,846	-5,508,400	-3,227,824
Income/(loss) from discontinued operations net of income taxes	-277,614	356,000	160,667	83,000	4,105,000	489,000	539,000	438,000	378,000	9,065,141	4,348,449	4,705,250	1,843,439
Net (loss)/income	-744,170	-2,023,000	-613,912	-952,000	2,786,000	-587,000	-220,000	-243,000	-334,000	6,880,152	1,219,603	-803,150	-1,384,385
Net (loss)/income attributable to common stockholders	($770,930)	($2,049,000)	($640,078)	($978,000)	$2,762,000	($612,000)	($254,000)	($269,000)	($369,000)	$6,796,522	$1,143,442	($905,477)	($1,504,139)
Net loss per share from continuing operations:
Basic (in dollars per share)	($0.03)	($0.16)	($0.05)	($0.07)	($0.09)	($0.08)	($0.05)	($0.05)	($0.05)	($0.15)	($0.22)	($0.38)	($0.23)
Diluted (in dollars per share)	($0.03)	($0.16)	($0.05)	($0.07)	($0.09)	($0.08)	($0.05)	($0.05)	($0.05)	($0.15)	($0.22)	($0.38)	($0.23)
Net income/(loss) per share from discontinued operations:
Basic (in dollars per share)	($0.02)	$0.03	$0.01	$0.01	$0.29	$0.03	$0.04	$0.03	$0.03	$0.61	$0.30	$0.33	$0.13
Diluted (in dollars per share)	($0.02)	$0.03	$0.01	$0.01	$0.29	$0.03	$0.04	$0.03	$0.03	$0.61	$0.30	$0.33	$0.13
Net (loss)/income attributable to common stockholders:
Basic (in dollars per share)	($0.05)	($0.14)	($0.04)	($0.07)	$0.20	($0.04)	($0.02)	($0.02)	($0.03)	$0.46	$0.08	($0.06)	($0.11)
Diluted (in dollars per share)	($0.05)	($0.14)	($0.04)	($0.07)	$0.20	($0.04)	($0.02)	($0.02)	($0.03)	$0.46	$0.08	($0.06)	($0.11)
Weighted average shares:
Basic and Diluted	15,016,429	14,488,060	14,441,707	14,362,494	14,011,814	14,008,772	13,939,938	13,892,816	13,850,667	14,821,619	14,285,829	14,336,135	13,930,267

Discontinued_Operations_Additi

Discontinued Operations - Additional Information (Detail) (USD $)	3 Months Ended									9 Months Ended		12 Months Ended		0 Months Ended		1 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Jan. 21, 2014	Mar. 01, 2013	Dec. 31, 2013	Mar. 31, 2013	Oct. 31, 2014	Jan. 20, 2014	Feb. 28, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net revenues	$0		$1,578,308							$0	$4,343,391	$5,909,375	$8,883,202
Sale price of assets to affiliates														30,000,000	6,100,000
Gain on sale, net of income taxes	-277,562		-233,889							9,093,268	3,448,270	3,391,451	0
Net income per share from discontinued operations, diluted (in dollars per share)	($0.02)	$0.03	$0.01	$0.01	$0.29	$0.03	$0.04	$0.03	$0.03	$0.61	$0.30	$0.33	$0.13
Sales
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group accounted percentage of revenue and cost of revenue												12.00%
Cost of Revenues
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group accounted percentage of revenue and cost of revenue												10.00%
Medical Shape Sensing Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Group accounted percentage of cost of revenue accounted to revenue cost												9.00%
Sale price of assets to affiliates														30,000,000
Cash consideration received at closing														12,000,000
Current assets related to disposal group		200,000										200,000				200,000
Long-term assets related to disposal group		200,000										200,000				200,000			300,000
Transaction costs incurred related to disposal group sales														1,300,000
Cash consideration received in future tied to achievement of technical specifications														8,000,000
Cash consideration received in future, potential future royalties														10,000,000
Medical Shape Sensing Business \| Sales
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group accounted percentage of revenue and cost of revenue												12.00%
Secure Computing and Communications Group (SCC)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Escrow deposits related to SCC group sales																125,000
Escrow release period																18 months
Sublease income										106,000							400,000
Group accounted percentage of cost of revenue accounted to revenue cost													20.70%
Net revenues												1,700,000
Sale price of assets to affiliates															6,100,000
Employees of disposal group transferred to purchaser															20
Current assets related to disposal group																				200,000
Long-term assets related to disposal group																				100,000
Purchase price receivable on sale of disposal group		110,000										110,000			5,400,000	110,000
Purchase price received from escrow																475,000
Transaction costs incurred related to disposal group sales															900,000
Gain on sale, net of income taxes												3,300,000
Net income per share from discontinued operations, diluted (in dollars per share)												$0.23
Secure Computing and Communications Group (SCC) \| Sales
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal group accounted percentage of revenue and cost of revenue													18.50%
Subsequent Event \| Medical Shape Sensing Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price of assets to affiliates														30,000,000
Cash consideration received at closing														6,000,000
Cash consideration received within 90 days of closing														6,000,000
Period after closing, which additional cash payments received														90 days
Cash consideration received in future tied to achievement of milestones and royalties														18,000,000
Employees of disposal group transferred to purchaser														10
Subsequent Event \| Secure Computing and Communications Group (SCC)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Purchase price received from escrow																		$125,000

Discontinued_Operations_Compon

Discontinued Operations - Components of (Loss) Income from Discontinued Operations (Detail) (USD $)	3 Months Ended									9 Months Ended		12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Discontinued Operations and Disposal Groups [Abstract]
Net revenues	$0		$1,578,308							$0	$4,343,391	$5,909,375	$8,883,202
Cost of revenues	0		927,847							46,204	2,623,286	3,486,200	5,337,336
Operating expenses	0		0							0	229,745	229,745	574,446
Income/(loss) before income taxes	0		650,461							-46,204	1,490,360	2,193,430	2,971,420
Allocated tax expense/(benefit)	52		255,905							-18,077	590,181	879,819	1,127,981
Operating (loss)/ income from discontinued operations	-52		394,556							-28,127	900,179	1,313,611	1,843,439
Gain on sale, net of $1.5 million of related income taxes												3,391,639	0
(Loss)/gain on sale, net of related income taxes	-277,562		-233,889							9,093,268	3,448,270	3,391,451	0
(Loss)/income from discontinued operations, net of income taxes	($277,614)	$356,000	$160,667	$83,000	$4,105,000	$489,000	$539,000	$438,000	$378,000	$9,065,141	$4,348,449	$4,705,250	$1,843,439

Discontinued_Operations_Compon1

Discontinued Operations - Components of (Loss) Income from Discontinued Operations (Parenthetical) (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Discontinued Operations and Disposal Groups [Abstract]
Gain on sale, related income taxes					$2.40	$1.10
Gain on sale, related income taxes	$0.30	$0.20	$1.60	$1.50	$1.50

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
	Sep. 30, 2014	Sep. 30, 2013	Segment	Sep. 30, 2013	Segment	Dec. 31, 2012	Dec. 31, 2011
Accounting Policies [Abstract]
Number of operating segments			2		2
Expected dividend yield of stock options			0.00%		0.00%	0.00%
Outstanding stock options (in shares)	4,448,259		4,448,259		5,279,229	5,422,130	4,641,039
Outstanding stock options, weighted average remaining contractual term			6 years 3 months 18 days
Exercisable stock options (in shares)	3,055,457		3,055,457		4,012,378	3,775,388	3,206,994
Exercisable stock options, weighted average remaining contractual term			5 years
Stock-based compensation	$300,000	$300,000	$738,802	$896,554	$1,181,379	$1,882,533
Stock-based compensation expense expected to recognize	$1,600,000		$1,600,000		$1,600,000
Weighted average remaining service			1 year 7 months 6 days		1 year 8 months 12 days
Stock repurchased during period, shares			22,725
Average share price of repurchased stock (in usd per share)			$1.42

Basis_of_Presentation_and_Sign3

Basis of Presentation and Significant Accounting Policies - Per Share Net Loss from Continuing Operations and Net (Loss)/Income Attributable to Common Stockholders (Detail) (USD $)	3 Months Ended									9 Months Ended		12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Numerator:
Net loss from continuing operations	($466,556)	($2,379,000)	($774,579)	($1,035,000)	($1,319,000)	($1,076,000)	($759,000)	($681,000)	($712,000)	($2,184,989)	($3,128,846)	($5,508,400)	($3,227,824)
Net (loss)/income attributable to stockholders	($770,930)	($2,049,000)	($640,078)	($978,000)	$2,762,000	($612,000)	($254,000)	($269,000)	($369,000)	$6,796,522	$1,143,442	($905,477)	($1,504,139)
Denominator:
Basic net loss per share from continuing operations	($0.03)	($0.16)	($0.05)	($0.07)	($0.09)	($0.08)	($0.05)	($0.05)	($0.05)	($0.15)	($0.22)	($0.38)	($0.23)
Diluted net loss per share from continuing operations	($0.03)	($0.16)	($0.05)	($0.07)	($0.09)	($0.08)	($0.05)	($0.05)	($0.05)	($0.15)	($0.22)	($0.38)	($0.23)
Basic weighted average common shares outstanding	15,016,429		14,441,707							14,821,619	14,285,829
Weighted average common stock equivalents from assumed exercise of stock options and restricted stock awards	0		0							0	0
Convertible preferred stock	0		0							0	0
Preferred stock dividends	0		0							0	0
Diluted weighted average common shares outstanding	15,016,429		14,441,707							17,185,369	16,593,102
Basic net income per share attributable to common stockholders (in dollars per share)	($0.05)	($0.14)	($0.04)	($0.07)	$0.20	($0.04)	($0.02)	($0.02)	($0.03)	$0.46	$0.08	($0.06)	($0.11)
Diluted net income per share attributable to common stockholders (in dollars per share)	($0.05)	($0.14)	($0.04)	($0.07)	$0.20	($0.04)	($0.02)	($0.02)	($0.03)	$0.46	$0.08	($0.06)	($0.11)
Continuing Operations
Denominator:
Basic weighted average common shares outstanding	15,016,429		14,441,707							14,821,619	14,285,829
Diluted weighted average common shares outstanding	15,016,429		14,441,707							14,821,619	14,285,829
Outstanding Stock Options
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	4,448,259		5,322,656							3,005,297	4,095,725
Outstanding Stock Options \| Continuing Operations
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	4,448,259		5,322,656							4,086,208	5,322,686
Convertible preferred stock
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	1,321,514		1,321,514							1,321,514	1,321,514
Convertible preferred stock \| Continuing Operations
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	1,321,514		1,321,514							1,321,514	1,321,514
Preferred stock
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	373,994		274,879							354,171	255,056
Preferred stock \| Continuing Operations
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	373,994		274,879							354,171	255,056
Restricted Stock
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	330,160		261,257							290,394	219,759
Restricted Stock \| Continuing Operations
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	330,160		261,257							290,394	219,759
Carillion Warrants
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	366,000		366,000							366,000	366,000
Carillion Warrants \| Continuing Operations
Denominator:
Antidilutive securities excluded from computation of earnings per share (in shares)	366,000		366,000							366,000	366,000

Basis_of_Presentation_and_Sign4

Basis of Presentation and Significant Accounting Policies - Assumptions Used to Estimate Fair Values of Option Granted (Detail)	9 Months Ended		12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	2.14%		1.27%	1.02%
Expected life of options (in years)	7 years 6 months	7 years 6 months	7 years 6 months	7 years 6 months
Expected stock price volatility	106.00%	108.00%	108.00%	108.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		1.27%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate		2.34%

Basis_of_Presentation_and_Sign5

Basis of Presentation and Significant Accounting Policies - Summary of Activity of 2003 stock Plan and 2006 Equity Incentive Plan (Detail) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Options Outstanding, Number of Shares
Beginning Balance (in shares)	5,279,229	5,422,130	4,641,039
Granted (in shares)	915,952	687,840	1,028,038
Exercised (in shares)	-276,586	-137,097	-182,702
Canceled (in shares)	-1,470,336
Ending Balance (in shares)	4,448,259	5,279,229	5,422,130
Options Outstanding, Price per Share Range
Beginning Balance, lower limit (in dollars per share)	$0.35
Beginning Balance, upper limit (in dollars per share)	$6.55	$6.74	$6.74
Granted, lower limit (in dollars per share)	$1.37	$1.20	$1.40
Granted, upper limit (in dollars per share)	$1.53	$1.31	$1.75
Exercised, lower limit (in dollars per share)	$0.35	$0.35	$0.35
Exercised, upper limit (in dollars per share)	$1.27	$1.18	$1.77
Canceled, lower limit (in dollars per share)	$0.35
Canceled, upper limit (in dollars per share)	$6.55
Balance Balance, lower limit (in dollars per share)	$0.35	$0.35
Balance Balance, upper limit (in dollars per share)	$6.55	$6.55	$6.74
Options Outstanding, Weighted Average Exercise Price
Beginning Balance (in dollars per share)	$2.11	$2.19	$2.23
Granted (in dollars per share)	$1.42	$1.29	$1.67
Exercised (in dollars per share)	$0.79	$0.56	$0.38
Canceled (in dollars per share)	$1.40
Ending balance (in dollars per share)	$1.92	$2.11	$2.19
Options Outstanding, Aggregate Intrinsic Value, Beginning Balance	$784,154	$639,904	$1,509,270
Options Outstanding, Aggregate Intrinsic Value, Ending Balance	494,279	784,154	639,904
Options Exercisable, Beginning Balance (in shares)	4,012,378	3,775,388	3,206,994
Options Exercisable, Ending Balance (in shares)	3,055,457	4,012,378	3,775,388
Options Exercisable, Weighted Average Exercise Price, Beginning Balance (in dollars per share)	$2.28	$2.37	$2.23
Options Exercisable, Weighted Average Exercise Price ending balance (in dollars per share)	$2.11	$2.28	$2.37
Options Exercisable, Aggregate Intrinsic Value, Beginning Balance	697,826	604,292	1,258,740
Options Exercisable, Aggregate Intrinsic Value ending balance	$459,175	$697,826	$604,292

Accrued_Liabilities_Detail

Accrued Liabilities (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Payables and Accruals [Abstract]
Accrued compensation	$2,111,858	$2,205,612	$1,648,064
Accrued sub-contracts	309,570	297,510
Accrued professional fees	20,885	279,991
Accrued income tax	162,105	13,143
Deferred rent	72,477	102,569
Royalties	344,383	291,442
Warranty reserve	61,850	56,700
Claims reserve	0	92,167
Accrued liabilities-other	375,328	207,451
Total Accrued Liabilities	$3,458,456	$3,546,585

Capital_Stock_and_Additional_P2

Capital Stock and Additional Paid-in Capital (Detail) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2014		Dec. 31, 2013	Dec. 31, 2012
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	$11,762,378		$11,272,192	$10,704,066
Begging balance (in shares)	14,527,335		14,009,280
Beginning Balance (in shares)	1,321,514		1,321,514
Beginning Balance (in shares)	0
Exercise of stock options (in shares)	276,586		137,097	182,702
Share-based compensation			1,166,379	1,862,533
Purchase of treasury stock (in shares)	22,725
Ending Balance	19,595,188		11,762,378	11,272,192
Ending Balance (in shares)	15,026,973		14,527,335	14,009,280
Ending Balance (in shares)	1,321,514		1,321,514	1,321,514
Ending Balance (in shares)	22,725		0
Preferred stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Ending Balance	1,322		1,322
Ending Balance (in shares)	1,321,514		1,321,514
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	14,842
Begging balance (in shares)	14,527,335
Exercise of stock options (in shares)	276,586
Exercise of stock options	277
Share-based compensation (in shares)	268,500
Share-based compensation	209
Stock dividends to Carilion Clinic	59	[1]
Ending Balance	15,387
Ending Balance (in shares)	15,072,421
Treasury Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	0
Beginning Balance (in shares)	0
Purchase of treasury stock	-32,221
Purchase of treasury stock (in shares)	-22,725
Ending Balance	-32,221
Ending Balance (in shares)	-22,725
Additional Paid in Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	62,756,571
Exercise of stock options	217,668
Share-based compensation	766,724
Stock dividends to Carilion Clinic	83,572	[1]
Ending Balance	$63,824,535

[1]	The stock dividends payable in connection with Carilion Clinic's Series A Preferred Stock will be issued subsequent to September 30, 2014. For the period from January 12, 2010, the original issue date of the Series A Preferred Stock, through September 30, 2014, the Series A Preferred Stock issued to Carilion has accrued $793,807 in dividends. The accrued and unpaid dividends as of September 30, 2014 will be paid by the issuance of 373,994 shares of our common stock upon Carilion's written request.

Capital_Stock_and_Additional_P3

Capital Stock and Additional Paid-in Capital (Parenthetical) (Detail) (USD $)	9 Months Ended
	Sep. 30, 2014
Stockholders Equity Note [Line Items]
Accrued dividends	793,807
Carilion Clinic \| Series A Preferred Stock
Stockholders Equity Note [Line Items]
Stock dividends for preferred shareholders	373,994

Operating_Segments_Additional_

Operating Segments - Additional Information (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
Operating Segments - Additional Information (Detail)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Number of operating segments			2		2
Sales
Segment Reporting Information [Line Items]
Percentage of total consolidated revenues by customer					12.00%
Sales \| International
Segment Reporting Information [Line Items]
Percentage of total consolidated revenues	15.00%	16.00%	16.00%	23.00%
Sales \| United States Government
Segment Reporting Information [Line Items]
Percentage of total consolidated revenues by customer	60.00%	62.00%	60.00%	56.00%	64.00%	66.00%

Operating_Segments_Revenues_an

Operating Segments - Revenues and Operating Loss for Reportable Segments Not Including Discontinued Operations (Detail) (USD $)	3 Months Ended									9 Months Ended		12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting Information [Line Items]
Technology development revenues	$3,067,022	$2,858,000	$3,130,206	$2,807,000	$2,627,000	$3,598,000	$3,691,000	$3,895,000	$3,943,000	$8,961,909	$8,564,743	$11,421,868	$15,126,834
Products and licensing revenues	2,303,508	1,841,000	1,568,646	2,024,000	1,478,000	1,986,000	2,021,000	1,993,000	2,338,000	6,108,799	5,070,441	6,911,707	8,338,967
Total revenues	5,370,530	4,699,000	4,698,852	4,831,000	4,105,000	5,584,000	5,712,000	5,888,000	6,281,000	15,070,708	13,635,184	18,333,575	23,465,801
Total operating loss	-719,990	-2,753,000	-1,302,012	-1,739,000	-2,241,000	-1,322,000	-1,020,000	-922,000	-867,000	-3,635,360	-5,283,232	-8,035,310	-4,130,077
Depreciation												500,000	800,000
Amortization												400,000	300,000
Technology Development
Segment Reporting Information [Line Items]
Total operating loss	-299,980		-259,486							-2,835,120	-599,303	-3,169,605	-1,703,370
Depreciation	49,592		86,413							160,327	272,570	286,894	499,439
Amortization	38,641		61,563							131,615	173,140	197,765	212,790
Products and Licensing
Segment Reporting Information [Line Items]
Total operating loss	-420,010		-1,042,526							-800,240	-4,683,929	-4,865,705	-2,426,707
Depreciation	37,247		43,304							109,037	161,426	266,862	266,327
Amortization	$29,022		$30,851							$90,087	$104,239	$183,956	$113,471

Operating_Segments_Assets_for_

Operating Segments - Assets for Reportable Segments (Detail) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Dec. 31, 2012
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$26,094,258	$19,704,075	$20,457,768
Property plant and equipment, and intangible assets	1,917,164	2,060,709	2,426,638
Technology Development
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	14,902,005	10,208,433	13,342,725
Property plant and equipment, and intangible assets	1,198,066	1,217,083	1,868,235
Products and Licensing
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	11,192,253	9,495,642	7,115,043
Property plant and equipment, and intangible assets	$899,816	$1,132,101	$996,242

Contingencies_and_Guarantees_A

Contingencies and Guarantees - Additional information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Dec. 31, 2013	Sep. 30, 2014
	purchase_order	Sep. 30, 2014
Loss Contingencies [Line Items]
Number of non-cancelable purchase orders executed	2
Non-cancelable purchase order commitment	$1.40
Non-cancelable purchase order delivery period	18 months
Non-cancelable purchase order commitment remained	1.4	0.7
Defense Contract Audit Agency \| Preliminary Audit Report
Loss Contingencies [Line Items]
Claimed cost, subject to potential penalty		$0.80